{"gene":"S100A16","run_date":"2026-04-28T20:42:06","timeline":{"discoveries":[{"year":2006,"finding":"S100A16 is a homodimeric EF-hand Ca²⁺-binding protein that binds two Ca²⁺ ions per dimer exclusively via the C-terminal EF-hand of each subunit (the N-terminal EF-hand lacks the conserved glutamate and is non-functional). Ca²⁺ binding induces conformational changes detected by Trp fluorescence, and in human S100A16 (but not mouse) a hydrophobic patch implicated in target-protein recognition is formed upon Ca²⁺ binding. In glioblastoma cells S100A16 accumulates in nucleoli and translocates to the cytoplasm upon Ca²⁺ stimulation.","method":"Recombinant protein purification, flow dialysis (Ca²⁺ binding stoichiometry/affinity), Trp fluorescence spectroscopy, in situ hybridization, immunohistochemistry, immunofluorescence localization","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1-2 — multiple orthogonal biochemical methods (flow dialysis, fluorescence, structural) in a single foundational paper; replicated biochemically by structural study PMID:21046186","pmids":["17030513"],"is_preprint":false},{"year":2010,"finding":"The homodimeric structure of human S100A16 was determined both in the apo and Ca²⁺-bound states by NMR and X-ray crystallography. Unlike most S100 proteins, the conformational rearrangement upon Ca²⁺ binding is minor, attributable to the absence of the glutamate residue at the end of the N-terminal EF-hand and to unusually strong hydrophobic interactions between helices 3 and 4 that stabilize the 'closed' conformation of the second EF-hand even after Ca²⁺ binding.","method":"NMR solution structure (apo and Ca²⁺-bound), X-ray crystallography (solid state); structures compared to functional Ca²⁺-binding data","journal":"Journal of biological inorganic chemistry","confidence":"High","confidence_rationale":"Tier 1 — dual structural determination (NMR + crystal) with mechanistic interpretation of low Ca²⁺ affinity","pmids":["21046186"],"is_preprint":false},{"year":2011,"finding":"S100A16 promotes adipogenesis and preadipocyte proliferation: overexpression in 3T3-L1 cells markedly enhances differentiation into adipocytes while reducing insulin-stimulated glucose uptake and AKT phosphorylation; siRNA knockdown inhibits adipogenesis. Immunoprecipitation showed S100A16 physically interacts with the tumor suppressor p53; S100A16 overexpression suppresses p53-responsive genes and knockdown activates them. Elevation of intracellular Ca²⁺ via ionophore causes nuclear exclusion of S100A16.","method":"Overexpression and RNAi in 3T3-L1 preadipocytes; Oil Red O staining; glucose uptake assay; AKT phosphorylation Western blot; co-immunoprecipitation (S100A16–p53); Ca²⁺ ionophore treatment with localization imaging","journal":"Endocrinology","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal functional assays plus co-IP interaction; replicated in subsequent studies","pmids":["21266506"],"is_preprint":false},{"year":2011,"finding":"High-calcium diet reduces nuclear S100A16 levels in 3T3-L1 preadipocytes (Ca²⁺ ionophore-induced nuclear exclusion), correlating with inhibition of adipogenesis and enhanced insulin sensitivity, demonstrating that Ca²⁺-driven cytoplasmic translocation of S100A16 is the mechanistic link between dietary calcium and adipogenesis suppression.","method":"Obese rat model; Western blot for S100A16 expression; 3T3-L1 preadipocyte Ca²⁺ ionophore treatment with subcellular localization; Oil Red O staining; AKT phosphorylation","journal":"Metabolism: clinical and experimental","confidence":"Medium","confidence_rationale":"Tier 2/3 — consistent with prior 3T3-L1 data but in vivo correlation plus in vitro mechanistic follow-up is single-lab","pmids":["21871643"],"is_preprint":false},{"year":2013,"finding":"S100A16 physically interacts with S100A14 as identified by yeast two-hybrid screen and confirmed by co-immunoprecipitation and double immunofluorescence. S100A14 overexpression leads to post-transcriptional upregulation of S100A16 protein (no change in mRNA), while S100A16 overexpression does not reciprocally upregulate S100A14, establishing a unidirectional regulatory relationship. Protein degradation of both S100A14 and S100A16 is independent of proteasomal and lysosomal pathways.","method":"Yeast two-hybrid screen; co-immunoprecipitation; double indirect immunofluorescence; cycloheximide chase assay; proteasome/lysosome inhibitor experiments; qRT-PCR and Western blot","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 1-2 — interaction identified by Y2H and confirmed by reciprocal Co-IP and imaging; post-transcriptional regulation confirmed by mRNA/protein discordance","pmids":["24086685"],"is_preprint":false},{"year":2013,"finding":"In bone marrow-derived mesenchymal stem cells (BM-MSCs), S100A16 overexpression stimulates adipogenesis and inhibits osteogenesis: it increases PPARγ promoter activity and decreases RUNX2 promoter activity. The ERK1/2 pathway mediates osteogenesis regulation whereas the JNK pathway mediates adipogenesis regulation by S100A16.","method":"S100A16 transgenic and knockout BM-MSCs; Oil Red O and Alizarin Red S staining; luciferase reporter assays (PPARγ and RUNX2 promoters); Western blot for p-ERK1/2 and p-JNK; RT-PCR for BMP2, RUNX2, PPARγ, C/EBPα","journal":"Molecular biology reports","confidence":"Medium","confidence_rationale":"Tier 2 — luciferase reporter + pathway Western blots, single-lab study","pmids":["23526364"],"is_preprint":false},{"year":2014,"finding":"S100A16 overexpression in MCF-7 breast cancer cells upregulates Notch1, ZEB1, and ZEB2, which repress E-cadherin and β-catenin and increase N-cadherin and vimentin (EMT markers). Notch1 siRNA knockdown reverses the EMT induced by S100A16 overexpression, placing Notch1 as a critical downstream effector of S100A16-driven EMT.","method":"Retroviral overexpression in MCF-7; siRNA knockdown of Notch1; Western blot and qRT-PCR for EMT markers; proliferation, colony formation, migration, and invasion assays","journal":"Journal of biomedical science","confidence":"Medium","confidence_rationale":"Tier 2/3 — epistasis established by siRNA rescue; single-lab with multiple phenotypic readouts","pmids":["25287362"],"is_preprint":false},{"year":2014,"finding":"Estrogen (E2) suppresses adipogenesis by inhibiting S100A16 expression; luciferase assay showed E2 directly inhibits the S100A16 promoter. Overexpression of S100A16 reversed E2-induced inhibition of adipogenesis, placing S100A16 downstream of estrogen signaling in adipogenic regulation.","method":"Ovariectomized rat model; mouse embryonic fibroblast adipogenesis assay; luciferase reporter assay (S100A16 promoter); S100A16 overexpression rescue experiment; Western blot for PPARγ, aP2, C/EBPα, S100A16","journal":"Journal of molecular endocrinology","confidence":"Medium","confidence_rationale":"Tier 2 — promoter luciferase + genetic rescue experiment; single lab","pmids":["24501224"],"is_preprint":false},{"year":2015,"finding":"In oral squamous cell carcinoma (OSCC), S100A16 overexpression promotes differentiation and acts as a tumor suppressor: it reduces cell proliferation, sphere formation, 3D-invasive ability, and tumorigenesis in a mouse xenograft model. Mechanistically, S100A16 overexpression downregulates self-renewal markers Bmi-1 and Oct4A and invasion-related MMP1 and MMP9, while knockdown has opposite effects.","method":"Retroviral overexpression and knockdown in CaLH3 and H357 cells; proliferation, sphere formation, 3D organotypic invasion assays; mouse xenograft model; Western blot and qRT-PCR for differentiation, self-renewal, and invasion markers","journal":"BMC cancer","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal in vitro assays plus in vivo xenograft validation; both gain- and loss-of-function","pmids":["26353754"],"is_preprint":false},{"year":2016,"finding":"S100A16 promotes prostate cancer cell invasion, migration, and proliferation via activation of AKT and ERK signaling pathways and downstream downregulation of tumor suppressors p21 and p27. Specific inhibitors of AKT (LY294002) and ERK (PD98059) suppressed the S100A16-induced clone formation and invasion, functionally confirming pathway placement.","method":"Stable overexpression and shRNA knockdown in DU-145/PC-3 cells; Transwell invasion/migration, wound healing, colony formation; Western blot for p-AKT, p-ERK, p21, p27; pharmacological pathway inhibition","journal":"Tumour biology","confidence":"Medium","confidence_rationale":"Tier 2/3 — pharmacological epistasis plus gain/loss-of-function; single lab","pmids":["27240591"],"is_preprint":false},{"year":2018,"finding":"Brain microvascular endothelial cell (HBMEC) exosomes transfer S100A16 protein to SCLC cells, inducing its elevation and translocation from the cytoplasm to the nucleus. Elevated S100A16 in SCLC cells prevents loss of mitochondrial membrane potential (Δψm) and confers resistance to apoptosis under stress. This protective effect depends on prohibitin (PHB)-1, a mitochondrial inner membrane protein: PHB-1 siRNA knockdown in S100A16-overexpressing cells abolishes the protective phenotype, placing PHB-1 downstream of S100A16 in mitochondrial protection.","method":"Co-culture with HBMEC; GW4869 exosome-release inhibition; ultracentrifugation-purified exosome treatment; Western blot and immunofluorescence for S100A16 localization; Annexin V/PI apoptosis assay; JC-1 mitochondrial membrane potential assay; PHB-1 siRNA epistasis","journal":"FASEB journal","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal functional assays plus epistasis via PHB-1 siRNA; exosome mechanism confirmed by inhibitor control","pmids":["30183374"],"is_preprint":false},{"year":2018,"finding":"In cancer stem-like spheroid cells from Yumoto cervical carcinoma, S100A16 positively regulates the stem cell transcription factors Oct4 and Nanog at the protein level. S100A16 knockdown decreases Oct4 and Nanog protein and reduces spheroid size. The proteasome inhibitor lactacystin blocks the S100A16-knockdown-induced decrease of Oct4/Nanog protein, indicating that S100A16 normally suppresses proteasomal degradation of p53 (which in turn represses Oct4/Nanog).","method":"Sphere formation assay; siRNA knockdown of S100A16; RT-PCR and Western blot for Oct4, Nanog, p53, S100A16; proteasome inhibitor lactacystin treatment","journal":"Oncology letters","confidence":"Medium","confidence_rationale":"Tier 3 — mechanistic inference from inhibitor experiment; single lab, single cell line","pmids":["29928366"],"is_preprint":false},{"year":2019,"finding":"S100A16 interacts with calmodulin (CaM) and through this interaction regulates the AMPK signaling pathway (CaM/CAMKK2/AMPK) to promote hepatic lipid synthesis. S100A16 transgenic mice on high-fat diet develop significantly more severe fatty liver than wild-type, while knockdown mice are protected, confirming in vivo lipogenic function.","method":"S100A16 transgenic and knockdown C57BL/6 mice on HFD/NFD; serum TG and liver histology; co-immunoprecipitation (S100A16–calmodulin); RNA sequencing; Western blot for AMPK pathway proteins","journal":"Journal of cellular physiology","confidence":"Medium","confidence_rationale":"Tier 2 — co-IP interaction plus in vivo genetic models; single lab","pmids":["31069793"],"is_preprint":false},{"year":2019,"finding":"In bladder cancer chemoresistance, S100A16 expression is transcriptionally regulated by the EMT transcription factor Snail. S100A16 knockdown suppresses the AKT/Bcl-2 pathway, promotes apoptosis, and resensitizes mitomycin-C-resistant cells to the drug, placing S100A16 in a Snail → S100A16 → AKT/Bcl-2 anti-apoptosis axis.","method":"Proteomics of drug-resistant cell line (LC-MS/MS); RT-PCR and Western blot confirmation; siRNA knockdown of S100A16; CCK8 chemosensitivity assay; Western blot for AKT, Bcl-2, EMT markers","journal":"Cancer management and research","confidence":"Medium","confidence_rationale":"Tier 2/3 — proteomics discovery plus functional siRNA validation; single lab","pmids":["31118765"],"is_preprint":false},{"year":2020,"finding":"S100A16 interacts with myosin-9 in response to elevated Ca²⁺ and TGF-β stimulation in renal tubular (HK-2) cells, promoting cytoskeletal reorganization (F-actin remodeling) and EMT progression during renal tubulointerstitial fibrosis. S100A16 transgenic mice subjected to unilateral ureteral obstruction (UUO) show exacerbated fibrosis compared to heterozygous knockout mice.","method":"Mass spectrometry pulldown to identify S100A16 binding partners; UUO mouse model with S100A16 transgenic and knockout mice; immunohistochemistry; Western blot for EMT and fibrosis markers; F-actin immunofluorescence in S100A16 OE/KD HK-2 cells; Ca²⁺ stimulation experiments","journal":"Cell death & disease","confidence":"High","confidence_rationale":"Tier 2 — MS-based interactor identification confirmed in genetic mouse models with multiple functional readouts","pmids":["32094322"],"is_preprint":false},{"year":2020,"finding":"In pancreatic ductal adenocarcinoma (PDAC), S100A16 induces EMT via enhanced expression of TWIST1 and activation of the STAT3 signaling pathway, promoting metastasis in vitro and in vivo. Combination of S100A16 downregulation with gemcitabine shows synergistic antitumor effects.","method":"In vitro knockdown/overexpression in PDAC cell lines; in vivo xenograft; Western blot for TWIST1, STAT3 activation, and EMT markers; GEO/TCGA database correlation analysis","journal":"Biochemical pharmacology","confidence":"Medium","confidence_rationale":"Tier 2/3 — in vivo plus in vitro functional data; mechanism via TWIST1/STAT3 supported by Western blot but no direct promoter or rescue experiments","pmids":["33359364"],"is_preprint":false},{"year":2021,"finding":"S100A16 physically interacts with GRP78 (an ER chaperone and master regulator of ER stress) in HK-2 renal tubular cells, with colocalization occurring primarily in the ER under normal conditions. S100A16 overexpression causes GRP78 to translocate into the cytoplasm where it competes with IRE1α for GRP78 binding. Freed IRE1α becomes phosphorylated, leading to XBP1 splicing and ER stress activation. Ca²⁺ chelation with BAPTA-AM suppresses cytoplasmic colocalization of S100A16 and GRP78 and blocks downstream ER stress and fibrosis gene induction.","method":"Co-immunoprecipitation (S100A16–GRP78, competitive binding with IRE1α); immunofluorescence colocalization; Lenti-S100A16 overexpression; UUO mouse model; Western blot for ER stress markers (GRP78, p-IRE1α, XBP1s); BAPTA-AM Ca²⁺ chelation experiment","journal":"Cell death & disease","confidence":"High","confidence_rationale":"Tier 2 — co-IP confirmed interaction, competitive binding shown, Ca²⁺ dependence demonstrated, in vivo model corroborates","pmids":["34645789"],"is_preprint":false},{"year":2021,"finding":"S100A16 promotes pancreatic cancer cell proliferation, migration, invasion, and metastasis via AKT and ERK1/2 signaling in a fibroblast growth factor 19 (FGF19)-dependent manner. S100A16 knockdown induces G2/M cell cycle arrest and apoptosis in PDAC cells.","method":"siRNA knockdown and overexpression in PDAC cell lines; in vivo metastasis model; Western blot for AKT, ERK1/2 activation; flow cytometry for cell cycle and apoptosis; FGF19 dependency validated by rescue experiments","journal":"Cell biology and toxicology","confidence":"Medium","confidence_rationale":"Tier 2/3 — FGF19-dependent pathway placement supported by rescue, single lab","pmids":["33389337"],"is_preprint":false},{"year":2021,"finding":"In gastric cancer cells, S100A16 promotes EMT, invasion, and migration via ZO-2 (Zonula Occludens-2) ubiquitination and degradation. Proteomic analysis identified ZO-2 as an S100A16 interacting protein; excessive S100A16 causes ZO-2 loss through ubiquitin-mediated degradation.","method":"Proteomic interactome analysis; co-IP; ubiquitination assay; Western blot for ZO-2, EMT markers; in vivo and in vitro proliferation and migration assays","journal":"Frontiers in cell and developmental biology","confidence":"Medium","confidence_rationale":"Tier 2/3 — proteomics-identified interaction confirmed by co-IP; ubiquitination mechanism via single-lab assay","pmids":["34650982"],"is_preprint":false},{"year":2021,"finding":"ADAMTS19 suppresses gastric cancer cell migration and invasion by binding cytoplasmic P65 (NF-κB), reducing nuclear P65 phosphorylation, and thereby downregulating S100A16 transcription. Overexpression of S100A16 reverses the migration/invasion suppression by ADAMTS19, placing S100A16 as a direct downstream transcriptional target of the NF-κB pathway in gastric cancer.","method":"Co-immunoprecipitation (ADAMTS19–P65); immunofluorescence; dual-luciferase reporter for NF-κB/S100A16; gain- and loss-of-function assays; S100A16 rescue experiments","journal":"Biomolecules","confidence":"Medium","confidence_rationale":"Tier 2 — co-IP plus luciferase reporter epistasis; single lab","pmids":["33921267"],"is_preprint":false},{"year":2022,"finding":"S100A16 promotes acute kidney injury (AKI) by activating the E3 ubiquitin ligase HRD1, which ubiquitinates and degrades the Wnt/β-catenin pathway negative regulators GSK3β and CK1α, thereby activating β-catenin signaling and inhibiting HGF secretion. S100A16 knockout in mice subjected to ischemia-reperfusion injury impeded Wnt/β-catenin activation and rescued HGF expression.","method":"S100A16 knockout mice + ischemia-reperfusion injury model; NRK-49F renal fibroblast overexpression/knockdown; Western blot for HRD1, GSK3β, CK1α, β-catenin, HGF; ubiquitination assays; ICG-001 (Wnt inhibitor) epistasis","journal":"Cellular and molecular life sciences","confidence":"High","confidence_rationale":"Tier 2 — in vivo genetic model + ubiquitination mechanism + pharmacological epistasis, multiple orthogonal methods","pmids":["35279748"],"is_preprint":false},{"year":2022,"finding":"S100A16 deficiency prevents hepatic stellate cell (HSC) activation and liver fibrosis. Mechanistically, S100A16 binds p53 protein and promotes its degradation; reduced p53 leads to increased CXCR4 expression, which activates ERK1/2 and AKT signaling to drive HSC activation. S100a16 transgenic mice develop spontaneous liver fibrosis, confirming gain-of-function pro-fibrotic activity.","method":"S100a16 knockout and transgenic mice in multiple liver fibrosis models; HSC isolation; RNA sequencing; co-IP (S100A16–p53); Western blot for CXCR4, p-ERK1/2, p-AKT; S100a16 genetic silencing in HSCs","journal":"Metabolism: clinical and experimental","confidence":"High","confidence_rationale":"Tier 2 — in vivo genetic models (KO + Tg) + RNA-seq + co-IP mechanism; strong preponderance","pmids":["35914619"],"is_preprint":false},{"year":2022,"finding":"Downregulation of S100A16 (together with HSP27) in placenta-derived multipotent cells (PDMCs) is sufficient to drive differentiation into functional astrocytes without chemical induction. Co-silencing S100A16 and HSP27 produces cells with classical astrocytic morphology, expression of astrocyte markers, and functional electrophysiology and Ca²⁺ influx characteristics.","method":"siRNA co-silencing of S100A16 and HSP27; immunofluorescence for neural/astrocyte markers; electrophysiology; Ca²⁺ influx assay; morphology imaging","journal":"Stem cell reviews and reports","confidence":"Medium","confidence_rationale":"Tier 2/3 — functional differentiation with multiple validation methods but mechanistic pathway not resolved; single lab","pmids":["35061207"],"is_preprint":false},{"year":2024,"finding":"HIF-1α transcriptionally upregulates HRD1 by binding to the HRD1 promoter (confirmed by ChIP and luciferase assay) within the S100A16-HRD1-GSK3β/CK1α signaling axis in renal hypoxia injury. The transcription factor TFAP2B was identified as a direct transcriptional activator of S100A16 (confirmed by ChIP and luciferase reporter assay), placing TFAP2B upstream of S100A16 in the hypoxic kidney injury pathway.","method":"Chromatin immunoprecipitation (ChIP) for HIF-1α at HRD1 promoter and TFAP2B at S100A16 promoter; luciferase reporter assays; S100A16 knockout rat tubular epithelial cells (NRK-52E); hypoxia/reoxygenation model; IRI mouse model; Western blot","journal":"Cell death & disease","confidence":"High","confidence_rationale":"Tier 1-2 — ChIP + luciferase reporter confirm transcriptional regulation; in vivo and in vitro models with genetic KO","pmids":["38710691"],"is_preprint":false},{"year":2024,"finding":"S100A16 binds to the RNA helicase MOV10 (confirmed by co-immunoprecipitation) and positively modulates MOV10 expression in lung adenocarcinoma cells. MOV10 in turn binds ITGA3 mRNA (confirmed by RNA immunoprecipitation) and stabilizes it (confirmed by actinomycin D chase assay), thereby activating ECM-receptor interaction pathways to promote LUAD malignant progression.","method":"Co-immunoprecipitation (S100A16–MOV10); RNA immunoprecipitation (MOV10–ITGA3 mRNA); actinomycin D mRNA stability assay; siRNA knockdown; Western blot; proliferation, migration, invasion, angiogenesis assays","journal":"Molecular medicine reports","confidence":"Medium","confidence_rationale":"Tier 2 — co-IP + RIP + mRNA stability assay; single lab but multiple orthogonal methods","pmids":["39450567"],"is_preprint":false},{"year":2024,"finding":"VDAC1 upregulates NF-κB/p65 signaling after myocardial ischemia/reperfusion injury, and NF-κB/p65 binds the S100A16 promoter to transcriptionally activate S100A16 expression. Elevated S100A16 then interacts with calmodulin (CaM) in a Ca²⁺-dependent manner to dysregulate the CaMKK2/AMPK pathway, contributing to cardiomyocyte apoptosis, inflammation, and ROS production. Adenovirus-mediated S100A16 inhibition reduced infarct size and improved cardiac function.","method":"Left anterior descending artery ligation/release in vivo; cardiomyocyte H/R model; Western blot for VDAC1, p-NF-κB/p65, S100A16, CaMKK2, AMPK; NF-κB/p65 promoter binding (ChIP implied); S100A16–CaM co-interaction; adenovirus-mediated S100A16 knockdown; cardiac function (echocardiography); flow cytometry for apoptosis/ROS","journal":"European journal of pharmacology","confidence":"Medium","confidence_rationale":"Tier 2/3 — in vivo model + Ca²⁺-CaM interaction + pathway Western blots; CaM interaction inferred functionally; single lab","pmids":["39613175"],"is_preprint":false},{"year":2024,"finding":"SPDEF transcription factor enhances transcription of S100A16, which in turn activates the PI3K/AKT signaling pathway to promote pancreatic adenocarcinoma cell migration, proliferation, and invasion. S100A16 was identified as one of four key SPDEF-regulated genes by integrative genomic analysis.","method":"TCGA database mining; in vitro overexpression/knockdown; Western blot for PI3K/AKT activation; qRT-PCR; proliferation and invasion assays; SPDEF–S100A16 transcriptional correlation","journal":"Biomolecules & biomedicine","confidence":"Low","confidence_rationale":"Tier 3/4 — transcriptional regulation inferred from expression correlation and functional assays; no direct promoter binding confirmed","pmids":["38520747"],"is_preprint":false},{"year":2025,"finding":"S100A16 knockdown in HeLa and SiHa cervical cancer cells inhibits migration without affecting viability. RNA sequencing revealed S100A16 transcriptionally regulates Ribophorin II (RPN2); S100A16 silencing decreases RPN2 through reduced p-STAT3, which in turn decreases p-GSK3β and prevents nuclear translocation of β-catenin, suppressing the β-catenin/TCF pathway and cell migration.","method":"S100A16 siRNA knockdown; RNA sequencing; Western blot for RPN2, p-STAT3, p-GSK3β, β-catenin; nuclear/cytosolic fractionation; cell migration assay; RPN2 overexpression rescue","journal":"Biochimica et biophysica acta. Molecular cell research","confidence":"Medium","confidence_rationale":"Tier 2/3 — RNA-seq pathway discovery + rescue experiment + fractionation; single lab","pmids":["40907797"],"is_preprint":false},{"year":2025,"finding":"S100A16 localizes to the nucleolus of metastatic breast cancer cells and associates with RNA Polymerase I (RPA194, the catalytic subunit of Pol I) at rDNA loci (detected by ChIP-MS). Loss of S100A16 disrupts RNA Polymerase I activation and rRNA synthesis, reverses EMT, inhibits invasion, and reduces metastatic incidence in animal models.","method":"Nucleolar proteomics from primary vs. metastatic breast cancer cell lines; ChIP-MS (S100A16 at rDNA with RPA194); S100A16 loss-of-function (siRNA/CRISPR); rRNA synthesis assay; EMT marker Western blot; invasion assay; in vivo metastasis model","journal":"Cell death & disease","confidence":"High","confidence_rationale":"Tier 1-2 — ChIP-MS confirms rDNA association with Pol I; functional rRNA synthesis assay; in vivo validation; multiple orthogonal methods","pmids":["40846689"],"is_preprint":false},{"year":2026,"finding":"S100A14 stabilizes S100A16 protein through post-translational modification (not transcriptional regulation), and the S100A14/S100A16 complex reduces p53 protein stability and inhibits p53 transcriptional activity and downstream p21 expression, promoting pancreatic cancer progression. Co-IP confirmed the S100A14–S100A16 protein interaction; CHX chase assay demonstrated S100A14-dependent S100A16 protein stabilization.","method":"Co-immunoprecipitation (S100A14–S100A16); cycloheximide (CHX) chase assay for protein stability; dual-luciferase assay for p53 transcriptional activity; siRNA knockdown; Western blot for p53, p21, EMT markers; CCK-8 and Transwell assays","journal":"Oncology research","confidence":"Medium","confidence_rationale":"Tier 2 — co-IP + CHX chase + luciferase reporter confirm post-translational stabilization and p53 suppression; single lab","pmids":["41799516"],"is_preprint":false}],"current_model":"S100A16 is a homodimeric Ca²⁺-binding EF-hand protein (functional Ca²⁺ binding only via the C-terminal EF-hand) that undergoes Ca²⁺-dependent nuclear-to-cytoplasmic translocation; in the nucleus it associates with rDNA and RNA Polymerase I to promote rRNA synthesis and cancer metastasis, and in the cytoplasm it interacts with multiple partners including p53 (promoting its degradation to drive adipogenesis and liver fibrosis), GRP78 (activating IRE1α-XBP1 ER stress via competitive binding), myosin-9 (driving cytoskeletal reorganization and renal EMT), calmodulin (dysregulating CaMKK2/AMPK signaling), and HRD1 (ubiquitinating GSK3β/CK1α to activate Wnt/β-catenin in kidney injury), while its expression is transcriptionally regulated upstream by TFAP2B, NF-κB/p65, and estrogen signaling, and its protein level is post-translationally stabilized by S100A14 heterodimerization."},"narrative":{"teleology":[{"year":2006,"claim":"Established that S100A16 is a homodimeric Ca²⁺-binding protein using only the C-terminal EF-hand, answering the fundamental question of how this atypical S100 member senses calcium and revealing its Ca²⁺-dependent nucleolar-to-cytoplasmic translocation.","evidence":"Recombinant protein flow dialysis, Trp fluorescence spectroscopy, immunofluorescence in glioblastoma cells","pmids":["17030513"],"confidence":"High","gaps":["Target-binding surface only inferred from hydrophobic patch exposure; no target protein identified","Mouse S100A16 did not expose a hydrophobic patch—species-specific functional differences unresolved"]},{"year":2010,"claim":"Atomic-resolution structures of apo and Ca²⁺-bound S100A16 explained why Ca²⁺-induced conformational change is unusually modest, resolving the paradox of weak target-protein interaction detected biochemically.","evidence":"Dual NMR solution structure and X-ray crystallography of human S100A16","pmids":["21046186"],"confidence":"High","gaps":["No structure of S100A16 bound to a target peptide or protein","Functional consequence of minimal conformational change for downstream signaling not tested"]},{"year":2011,"claim":"Identified the first cellular function—promotion of adipogenesis—and the first direct binding partner, p53, establishing that S100A16 suppresses p53-dependent transcription and that Ca²⁺-induced cytoplasmic translocation regulates this adipogenic activity.","evidence":"Overexpression/RNAi in 3T3-L1 preadipocytes; co-immunoprecipitation of S100A16–p53; Ca²⁺ ionophore translocation","pmids":["21266506","21871643"],"confidence":"High","gaps":["Mechanism of p53 degradation not defined (direct or via E3 ligase)","Whether Ca²⁺-dependent translocation is required for all S100A16 functions unclear"]},{"year":2013,"claim":"Revealed that S100A14 heterodimerizes with S100A16 and stabilizes it post-translationally, and that S100A16 reciprocally regulates mesenchymal stem cell fate by promoting adipogenesis via JNK and inhibiting osteogenesis via ERK1/2.","evidence":"Yeast two-hybrid, co-IP, cycloheximide chase (S100A14–S100A16); luciferase reporters for PPARγ/RUNX2 in BM-MSCs","pmids":["24086685","23526364"],"confidence":"High","gaps":["Degradation pathway for S100A16 protein itself not identified (proteasome- and lysosome-independent)","S100A14–S100A16 stoichiometry and structural basis unresolved"]},{"year":2014,"claim":"Extended S100A16 function to cancer EMT: in breast cancer cells it drives Notch1-dependent E-cadherin loss, and estrogen signaling was shown to directly repress the S100A16 promoter, linking hormonal regulation to its adipogenic and EMT roles.","evidence":"Retroviral overexpression/Notch1 siRNA rescue in MCF-7; luciferase reporter for E2-mediated S100A16 promoter repression; ovariectomized rat model","pmids":["25287362","24501224"],"confidence":"Medium","gaps":["Notch1 activation mechanism by S100A16 not defined (direct interaction vs. transcriptional)","Estrogen receptor subtype mediating S100A16 repression not identified"]},{"year":2018,"claim":"Demonstrated that exosome-transferred S100A16 protects cancer cells from apoptosis via mitochondrial membrane potential maintenance dependent on prohibitin-1, and that S100A16 suppresses proteasomal degradation of p53 to maintain cancer stemness factors Oct4/Nanog.","evidence":"HBMEC exosome transfer to SCLC cells with PHB-1 epistasis; cervical carcinoma spheroid assay with proteasome inhibitor rescue","pmids":["30183374","29928366"],"confidence":"High","gaps":["Direct S100A16–PHB1 physical interaction not tested","Contradictory roles of S100A16 on p53 (degradation in adipogenesis vs. stabilization in stemness) not reconciled"]},{"year":2019,"claim":"Identified calmodulin as a direct S100A16 interactor mediating hepatic lipogenesis via the CaMKK2/AMPK axis, and placed S100A16 downstream of Snail in a chemoresistance circuit operating through AKT/Bcl-2.","evidence":"Co-IP (S100A16–CaM) in transgenic/knockout mice on HFD; siRNA knockdown in drug-resistant bladder cancer cells","pmids":["31069793","31118765"],"confidence":"Medium","gaps":["Whether S100A16 competes with Ca²⁺/CaM targets or modulates CaM conformation not distinguished","Snail–S100A16 transcriptional regulation not confirmed by promoter binding assay"]},{"year":2020,"claim":"Identified myosin-9 as a Ca²⁺-dependent S100A16 partner driving actin cytoskeletal reorganization and renal EMT, validated in transgenic and knockout mice undergoing ureteral obstruction.","evidence":"Mass spectrometry pulldown for S100A16 partners; UUO model in S100A16 transgenic/heterozygous-KO mice; F-actin immunofluorescence","pmids":["32094322"],"confidence":"High","gaps":["Binding interface on myosin-9 and whether S100A16 modulates myosin ATPase activity unknown","Relative contribution of myosin-9 vs. GRP78 pathways in renal fibrosis not delineated"]},{"year":2021,"claim":"Defined a competitive binding mechanism at the ER: S100A16 sequesters GRP78 away from IRE1α, triggering IRE1α autophosphorylation and XBP1 splicing, establishing S100A16 as a Ca²⁺-dependent activator of the unfolded protein response in renal fibrosis.","evidence":"Co-IP showing competitive S100A16–GRP78 vs. IRE1α–GRP78 binding; BAPTA-AM reversal; UUO mouse model","pmids":["34645789"],"confidence":"High","gaps":["Whether S100A16–GRP78 interaction occurs at other ER stress branches (PERK, ATF6) not tested","Structural basis for GRP78 competition not resolved"]},{"year":2021,"claim":"Placed S100A16 downstream of NF-κB/p65 transcriptional control in gastric cancer, and identified ZO-2 as an interaction partner whose ubiquitin-dependent degradation drives S100A16-mediated EMT and invasion.","evidence":"Dual-luciferase reporter for NF-κB at S100A16 promoter; ADAMTS19–P65 co-IP; proteomic identification and co-IP of S100A16–ZO-2; ubiquitination assay","pmids":["33921267","34650982"],"confidence":"Medium","gaps":["E3 ligase responsible for ZO-2 ubiquitination downstream of S100A16 not identified","Whether NF-κB regulation of S100A16 is tissue-general or gastric cancer–specific unknown"]},{"year":2022,"claim":"Established that S100A16 binds p53 to promote its degradation in hepatic stellate cells, driving CXCR4/ERK/AKT-dependent liver fibrosis, and that HRD1-mediated ubiquitination of GSK3β/CK1α downstream of S100A16 activates Wnt/β-catenin signaling in acute kidney injury—both validated by genetic knockout in vivo.","evidence":"S100A16-KO and transgenic mice in liver fibrosis and renal IRI models; co-IP (S100A16–p53); ubiquitination assays (HRD1–GSK3β/CK1α); Wnt inhibitor epistasis","pmids":["35914619","35279748"],"confidence":"High","gaps":["Whether S100A16 directly activates HRD1 E3 ligase activity or recruits substrates not distinguished","How p53 degradation is mechanistically accomplished (proteasomal pathway involvement) remains incomplete"]},{"year":2024,"claim":"Identified TFAP2B as a direct transcriptional activator of S100A16 via ChIP, and confirmed that S100A16–calmodulin interaction mediates cardiomyocyte injury after ischemia/reperfusion through the CaMKK2/AMPK pathway downstream of NF-κB/p65 promoter activation.","evidence":"ChIP and luciferase assay (TFAP2B at S100A16 promoter; HIF-1α at HRD1 promoter); S100A16-KO rat cells; myocardial IRI model with adenoviral knockdown","pmids":["38710691","39613175"],"confidence":"High","gaps":["Whether TFAP2B and NF-κB/p65 cooperate at the S100A16 promoter or act in distinct tissues not tested","Upstream signals activating TFAP2B in hypoxia not defined"]},{"year":2025,"claim":"Revealed that S100A16 localizes to the nucleolus and associates with RNA Polymerase I at rDNA loci, directly promoting rRNA synthesis; its loss reverses EMT and reduces metastasis, connecting ribosome biogenesis to the metastatic program.","evidence":"ChIP-MS (S100A16 at rDNA with RPA194); rRNA synthesis assay; CRISPR knockout; in vivo metastasis model in breast cancer","pmids":["40846689"],"confidence":"High","gaps":["Mechanism by which S100A16 activates Pol I (cofactor recruitment vs. chromatin remodeling) not defined","Whether nucleolar function is Ca²⁺-dependent or constitutive not tested"]},{"year":null,"claim":"Key unresolved questions include the structural basis for S100A16 target discrimination among its many partners, how its apparently opposing effects on p53 (degradation in adipogenesis/fibrosis vs. stabilization in stemness) are contextually regulated, and the relative contribution of nucleolar rRNA synthesis versus cytoplasmic EMT pathways to its pro-metastatic activity.","evidence":"","pmids":[],"confidence":"Low","gaps":["No co-crystal structure of S100A16 with any target protein","Context-dependent p53 regulation mechanism unresolved","Relative importance of nuclear vs. cytoplasmic functions in different disease settings not systematically compared"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[2,11,12,16,20,21,29]},{"term_id":"GO:0008092","term_label":"cytoskeletal protein binding","supporting_discovery_ids":[14]}],"localization":[{"term_id":"GO:0005730","term_label":"nucleolus","supporting_discovery_ids":[0,28]},{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[0,2,10]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[0,2,14,16]},{"term_id":"GO:0005783","term_label":"endoplasmic reticulum","supporting_discovery_ids":[16]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[2,5,6,9,13,15,17,20,25,27]},{"term_id":"R-HSA-8953854","term_label":"Metabolism of RNA","supporting_discovery_ids":[28]},{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[4,18,20,29]},{"term_id":"R-HSA-8953897","term_label":"Cellular responses to stimuli","supporting_discovery_ids":[16,25]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[10,13,25]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[2,5,22]}],"complexes":["S100A14/S100A16 heterodimer","S100A16 homodimer"],"partners":["S100A14","TP53","HSPA5","MYH9","CALM1","SYVN1","MOV10","POLR1A"],"other_free_text":[]},"mechanistic_narrative":"S100A16 is an EF-hand Ca²⁺-binding protein that functions as a Ca²⁺-dependent signaling hub linking nucleolar ribosome biogenesis, epithelial–mesenchymal transition, adipogenesis, and organ fibrosis. Structurally, it forms a homodimer that binds Ca²⁺ exclusively through the C-terminal EF-hand, with minimal conformational change upon Ca²⁺ binding owing to strong inter-helical hydrophobic contacts [PMID:17030513, PMID:21046186]. In the nucleus, S100A16 associates with RNA Polymerase I at rDNA loci to promote rRNA synthesis and metastasis [PMID:40846689]; Ca²⁺ elevation drives its translocation to the cytoplasm, where it engages diverse partners—p53 (promoting its degradation to drive adipogenesis and hepatic stellate cell activation) [PMID:21266506, PMID:35914619], GRP78 (competitively releasing IRE1α to activate ER stress) [PMID:34645789], myosin-9 (reorganizing the actin cytoskeleton during renal EMT) [PMID:32094322], calmodulin (dysregulating the CaMKK2/AMPK axis) [PMID:31069793, PMID:39613175], and the E3 ligase HRD1 (ubiquitinating GSK3β/CK1α to activate Wnt/β-catenin signaling in kidney injury) [PMID:35279748]. S100A16 protein levels are post-translationally stabilized by heterodimerization with S100A14, and its transcription is directly activated by TFAP2B and NF-κB/p65 and repressed by estrogen signaling [PMID:24086685, PMID:38710691, PMID:33921267, PMID:24501224]."},"prefetch_data":{"uniprot":{"accession":"Q96FQ6","full_name":"Protein S100-A16","aliases":["Aging-associated gene 13 protein","Protein S100-F","S100 calcium-binding protein A16"],"length_aa":103,"mass_kda":11.8,"function":"Calcium-binding protein. Binds one calcium ion per monomer (PubMed:17030513). Can promote differentiation of adipocytes (in vitro) (By similarity). Overexpression in preadipocytes increases their proliferation, enhances adipogenesis and reduces insulin-stimulated glucose uptake (By similarity)","subcellular_location":"Nucleus, nucleolus; Cytoplasm","url":"https://www.uniprot.org/uniprotkb/Q96FQ6/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/S100A16","classification":"Not Classified","n_dependent_lines":4,"n_total_lines":1208,"dependency_fraction":0.0033112582781456954},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/S100A16","total_profiled":1310},"omim":[{"mim_id":"617437","title":"S100 CALCIUM-BINDING PROTEIN A16; S100A16","url":"https://www.omim.org/entry/617437"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Cytosol","reliability":"Approved"},{"location":"Plasma membrane","reliability":"Additional"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"esophagus","ntpm":2382.1}],"url":"https://www.proteinatlas.org/search/S100A16"},"hgnc":{"alias_symbol":["S100F","DT1P1A7","MGC17528"],"prev_symbol":[]},"alphafold":{"accession":"Q96FQ6","domains":[{"cath_id":"1.10.238.10","chopping":"8-102","consensus_level":"high","plddt":83.6534,"start":8,"end":102}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q96FQ6","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q96FQ6-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q96FQ6-F1-predicted_aligned_error_v6.png","plddt_mean":81.12},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=S100A16","jax_strain_url":"https://www.jax.org/strain/search?query=S100A16"},"sequence":{"accession":"Q96FQ6","fasta_url":"https://rest.uniprot.org/uniprotkb/Q96FQ6.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q96FQ6/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q96FQ6"}},"corpus_meta":[{"pmid":"30183374","id":"PMC_30183374","title":"Brain microvascular endothelial cell exosome-mediated S100A16 up-regulation confers small-cell lung cancer cell survival in brain.","date":"2018","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/30183374","citation_count":70,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17030513","id":"PMC_17030513","title":"S100A16, a novel calcium-binding protein of the EF-hand superfamily.","date":"2006","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17030513","citation_count":66,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"14684152","id":"PMC_14684152","title":"S100A16, a ubiquitously expressed EF-hand protein which is up-regulated in tumors.","date":"2004","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/14684152","citation_count":64,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25287362","id":"PMC_25287362","title":"Up-regulation of S100A16 expression promotes epithelial-mesenchymal transition via Notch1 pathway in breast cancer.","date":"2014","source":"Journal of biomedical science","url":"https://pubmed.ncbi.nlm.nih.gov/25287362","citation_count":47,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26353754","id":"PMC_26353754","title":"S100A16 promotes differentiation and contributes to a less aggressive tumor phenotype in oral squamous cell carcinoma.","date":"2015","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/26353754","citation_count":46,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21266506","id":"PMC_21266506","title":"Identification of S100A16 as a novel adipogenesis promoting factor in 3T3-L1 cells.","date":"2011","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/21266506","citation_count":46,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27240591","id":"PMC_27240591","title":"S100A16 promotes cell proliferation and metastasis via AKT and ERK cell signaling pathways in human prostate cancer.","date":"2016","source":"Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/27240591","citation_count":44,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33389337","id":"PMC_33389337","title":"S100A16 promotes metastasis and progression of pancreatic cancer through FGF19-mediated AKT and ERK1/2 pathways.","date":"2021","source":"Cell biology and toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/33389337","citation_count":42,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34645789","id":"PMC_34645789","title":"The interaction of S100A16 and GRP78 actives endoplasmic reticulum stress-mediated through the IRE1α/XBP1 pathway in renal tubulointerstitial fibrosis.","date":"2021","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/34645789","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33359364","id":"PMC_33359364","title":"S100A16 induces epithelial-mesenchymal transition in human PDAC cells and is a new therapeutic target for pancreatic cancer treatment that synergizes with gemcitabine.","date":"2020","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/33359364","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23526364","id":"PMC_23526364","title":"S100A16 inhibits osteogenesis but stimulates adipogenesis.","date":"2013","source":"Molecular biology reports","url":"https://pubmed.ncbi.nlm.nih.gov/23526364","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35279748","id":"PMC_35279748","title":"S100A16 promotes acute kidney injury by activating HRD1-induced ubiquitination and degradation of GSK3β and CK1α.","date":"2022","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/35279748","citation_count":27,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35914619","id":"PMC_35914619","title":"S100a16 deficiency prevents hepatic stellate cells activation and liver fibrosis via inhibiting CXCR4 expression.","date":"2022","source":"Metabolism: clinical and experimental","url":"https://pubmed.ncbi.nlm.nih.gov/35914619","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33355370","id":"PMC_33355370","title":"S100A16 suppresses the proliferation, migration and invasion of colorectal cancer cells in part via the JNK/p38 MAPK pathway.","date":"2020","source":"Molecular medicine reports","url":"https://pubmed.ncbi.nlm.nih.gov/33355370","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31796150","id":"PMC_31796150","title":"MicroRNA-6884-5p Regulates the Proliferation, Invasion, and EMT of Gastric Cancer Cells by Directly Targeting S100A16.","date":"2019","source":"Oncology research","url":"https://pubmed.ncbi.nlm.nih.gov/31796150","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24086685","id":"PMC_24086685","title":"S100A14 interacts with S100A16 and regulates its expression in human cancer cells.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24086685","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31118765","id":"PMC_31118765","title":"S100A16 regulated by Snail promotes the chemoresistance of nonmuscle invasive bladder cancer through the AKT/Bcl-2 pathway.","date":"2019","source":"Cancer management and research","url":"https://pubmed.ncbi.nlm.nih.gov/31118765","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33921267","id":"PMC_33921267","title":"ADAMTS19 Suppresses Cell Migration and Invasion by Targeting S100A16 via the NF-κB Pathway in Human Gastric Cancer.","date":"2021","source":"Biomolecules","url":"https://pubmed.ncbi.nlm.nih.gov/33921267","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32094322","id":"PMC_32094322","title":"Interaction of calcium binding protein S100A16 with myosin-9 promotes cytoskeleton reorganization in renal tubulointerstitial fibrosis.","date":"2020","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/32094322","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21046186","id":"PMC_21046186","title":"Structural characterization of human S100A16, a low-affinity calcium binder.","date":"2010","source":"Journal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/21046186","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31069793","id":"PMC_31069793","title":"S100A16, a novel lipogenesis promoting factor in livers of mice and hepatocytes in vitro.","date":"2019","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/31069793","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34650982","id":"PMC_34650982","title":"Calcium Binding Protein S100A16 Expedites Proliferation, Invasion and Epithelial-Mesenchymal Transition Process in Gastric Cancer.","date":"2021","source":"Frontiers in cell and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/34650982","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29928366","id":"PMC_29928366","title":"S100A16 up-regulates Oct4 and Nanog expression in cancer stem-like cells of Yumoto human cervical carcinoma cells.","date":"2018","source":"Oncology letters","url":"https://pubmed.ncbi.nlm.nih.gov/29928366","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24501224","id":"PMC_24501224","title":"Estrogen suppresses adipogenesis by inhibiting S100A16 expression.","date":"2014","source":"Journal of molecular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/24501224","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37509106","id":"PMC_37509106","title":"An Update on S100A16 in Human Cancer.","date":"2023","source":"Biomolecules","url":"https://pubmed.ncbi.nlm.nih.gov/37509106","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38710691","id":"PMC_38710691","title":"HIF-1α participates in the regulation of S100A16-HRD1-GSK3β/CK1α pathway in renal hypoxia injury.","date":"2024","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/38710691","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31894756","id":"PMC_31894756","title":"S100A16 Regulates HeLa Cell through the Phosphatidylinositol 3 Kinase (PI3K)/AKT Signaling Pathway.","date":"2020","source":"Medical science monitor : international medical journal of experimental and clinical research","url":"https://pubmed.ncbi.nlm.nih.gov/31894756","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36224471","id":"PMC_36224471","title":"An inhibitor of BRD4, GNE987, inhibits the growth of glioblastoma cells by targeting C-Myc and S100A16.","date":"2022","source":"Cancer chemotherapy and pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/36224471","citation_count":13,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36176934","id":"PMC_36176934","title":"Calbindin S100A16 Promotes Renal Cell Carcinoma Progression and Angiogenesis via the VEGF/VEGFR2 Signaling Pathway.","date":"2022","source":"Contrast media & molecular imaging","url":"https://pubmed.ncbi.nlm.nih.gov/36176934","citation_count":13,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31399502","id":"PMC_31399502","title":"S100A16-induced adipogenesis is associated with up-regulation of 11 β-hydroxysteroid dehydrogenase type 1 (11β-HSD1).","date":"2019","source":"Bioscience reports","url":"https://pubmed.ncbi.nlm.nih.gov/31399502","citation_count":11,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30916375","id":"PMC_30916375","title":"S100A16 suppresses the growth and survival of leukaemia cells and correlates with relapse and relapse free survival in adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia.","date":"2019","source":"British journal of haematology","url":"https://pubmed.ncbi.nlm.nih.gov/30916375","citation_count":11,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21871643","id":"PMC_21871643","title":"S100A16 mediation of weight gain attenuation induced by dietary calcium.","date":"2011","source":"Metabolism: clinical and experimental","url":"https://pubmed.ncbi.nlm.nih.gov/21871643","citation_count":9,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36718596","id":"PMC_36718596","title":"New progress with calcium-binding protein S100A16 in digestive system disease.","date":"2023","source":"Expert review of gastroenterology & hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/36718596","citation_count":7,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37928262","id":"PMC_37928262","title":"S100a16 Deficiency Prevents Alcohol-induced Fatty Liver Injury via Inducing MANF Expression in Mice.","date":"2023","source":"International journal of biological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/37928262","citation_count":7,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36967030","id":"PMC_36967030","title":"miR-508-5p serves as an anti-oncogene by targeting S100A16 to regulate AKT signaling and epithelial-mesenchymal transition process in lung adenocarcinoma cells.","date":"2023","source":"The American journal of the medical sciences","url":"https://pubmed.ncbi.nlm.nih.gov/36967030","citation_count":7,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37955537","id":"PMC_37955537","title":"S100A16 cooperates with DEPDC1 to promote the progression and angiogenesis of nephroblastoma through PI3K/Akt/mTOR pathway.","date":"2023","source":"Polish journal of pathology : official journal of the Polish Society of Pathologists","url":"https://pubmed.ncbi.nlm.nih.gov/37955537","citation_count":6,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33389513","id":"PMC_33389513","title":"Interference of S100A16 suppresses lipid accumulation and inflammation in high glucose-induced HK-2 cells.","date":"2021","source":"International urology and nephrology","url":"https://pubmed.ncbi.nlm.nih.gov/33389513","citation_count":6,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36696241","id":"PMC_36696241","title":"Circular ribonucleic acid circ-FADS2 promotes colorectal cancer cell proliferation and invasion by regulating miR-498/S100A16.","date":"2023","source":"Journal of physiology and pharmacology : an official journal of the Polish Physiological Society","url":"https://pubmed.ncbi.nlm.nih.gov/36696241","citation_count":5,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37978469","id":"PMC_37978469","title":"Expression and gene regulatory network of S100A16 protein in cervical cancer cells based on data mining.","date":"2023","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/37978469","citation_count":5,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35061207","id":"PMC_35061207","title":"Downregulated Calcium-Binding Protein S100A16 and HSP27 in Placenta-Derived Multipotent Cells Induce Functional Astrocyte Differentiation.","date":"2022","source":"Stem cell reviews and reports","url":"https://pubmed.ncbi.nlm.nih.gov/35061207","citation_count":4,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"39450567","id":"PMC_39450567","title":"S100A16 stabilizes the ITGA3‑mediated ECM‑receptor interaction pathway to drive the malignant properties of lung adenocarcinoma cells via binding MOV10.","date":"2024","source":"Molecular medicine reports","url":"https://pubmed.ncbi.nlm.nih.gov/39450567","citation_count":3,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38924205","id":"PMC_38924205","title":"Resistance to gemcitabine is mediated by the circ_0036627/miR-145/S100A16 axis in pancreatic cancer.","date":"2024","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/38924205","citation_count":3,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38370382","id":"PMC_38370382","title":"LncRNA PRKCA-AS1 promotes LUAD progression and function as a ceRNA to regulate S100A16 by sponging miR-508-5p.","date":"2024","source":"Journal of Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/38370382","citation_count":3,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"39101576","id":"PMC_39101576","title":"Icariside II protects from marrow adipose tissue (MAT) expansion in estrogen-deficient mice by targeting S100A16.","date":"2024","source":"Journal of molecular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/39101576","citation_count":3,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"39613175","id":"PMC_39613175","title":"VDAC1-NF-κB/p65-mediated S100A16 contributes to myocardial ischemia/reperfusion injury by regulating oxidative stress and inflammatory response via calmodulin/CaMKK2/AMPK pathway.","date":"2024","source":"European journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/39613175","citation_count":2,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38733818","id":"PMC_38733818","title":"S100A16 is a potential target for reshaping the tumor microenvironment in the hypoxic context of liver cancer.","date":"2024","source":"International immunopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/38733818","citation_count":2,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"41594721","id":"PMC_41594721","title":"Correction: Jiang et al. ADAMTS19 Suppresses Cell Migration and Invasion by Targeting S100A16 via the NF-κB Pathway in Human Gastric Cancer. Biomolecules 2021, 11, 561.","date":"2025","source":"Biomolecules","url":"https://pubmed.ncbi.nlm.nih.gov/41594721","citation_count":2,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38520747","id":"PMC_38520747","title":"SPDEF drives pancreatic adenocarcinoma progression via transcriptional upregulation of S100A16 and activation of the PI3K/AKT signaling pathway.","date":"2024","source":"Biomolecules & biomedicine","url":"https://pubmed.ncbi.nlm.nih.gov/38520747","citation_count":1,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"40907797","id":"PMC_40907797","title":"S100A16 knockdown reduces RPN2 expression and inhibits β-catenin/TCF signaling, leading to suppressed metastasis in cervical cancer cells.","date":"2025","source":"Biochimica et biophysica acta. Molecular cell research","url":"https://pubmed.ncbi.nlm.nih.gov/40907797","citation_count":0,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"40846689","id":"PMC_40846689","title":"Nucleolar proteomics identifies S100A16 as a key nucleolar protein driving breast cancer metastasis.","date":"2025","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/40846689","citation_count":0,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"40688271","id":"PMC_40688271","title":"Validation of S100A16 as an asthma biomarker and its role in IL-13-induced bronchial epithelial cell injury.","date":"2025","source":"Journal of thoracic disease","url":"https://pubmed.ncbi.nlm.nih.gov/40688271","citation_count":0,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"41799516","id":"PMC_41799516","title":"S100A14 Facilitates Pancreatic Cancer Progression via S100A16-Mediated p53 Suppression.","date":"2026","source":"Oncology research","url":"https://pubmed.ncbi.nlm.nih.gov/41799516","citation_count":0,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"41722834","id":"PMC_41722834","title":"Integrative single-cell and spatial transcriptomic reveals S100A16+ tumor endothelial cells drive angiogenesis and immunosuppression in hepatocellular carcinoma.","date":"2026","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/41722834","citation_count":0,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"41868093","id":"PMC_41868093","title":"Integrated bioinformatics and immunohistochemical analysis reveal that S100A16 is correlated with mutational burden, immune evasion, and P53 expression in gastric adenocarcinoma.","date":"2026","source":"International journal of clinical and experimental pathology","url":"https://pubmed.ncbi.nlm.nih.gov/41868093","citation_count":0,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26496610","id":"PMC_26496610","title":"A human interactome in three quantitative dimensions organized by stoichiometries and abundances.","date":"2015","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/26496610","citation_count":1015,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"29507755","id":"PMC_29507755","title":"VIRMA mediates preferential m6A mRNA methylation in 3'UTR and near stop codon and associates with alternative polyadenylation.","date":"2018","source":"Cell discovery","url":"https://pubmed.ncbi.nlm.nih.gov/29507755","citation_count":829,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"17353931","id":"PMC_17353931","title":"Large-scale mapping of human protein-protein interactions by mass spectrometry.","date":"2007","source":"Molecular systems biology","url":"https://pubmed.ncbi.nlm.nih.gov/17353931","citation_count":733,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"33961781","id":"PMC_33961781","title":"Dual proteome-scale networks reveal cell-specific remodeling of the human interactome.","date":"2021","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/33961781","citation_count":705,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21873635","id":"PMC_21873635","title":"Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium.","date":"2011","source":"Briefings in bioinformatics","url":"https://pubmed.ncbi.nlm.nih.gov/21873635","citation_count":656,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21565611","id":"PMC_21565611","title":"Mapping the NPHP-JBTS-MKS protein network reveals ciliopathy disease genes and pathways.","date":"2011","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/21565611","citation_count":507,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"17643375","id":"PMC_17643375","title":"Systematic analysis of the protein interaction network for the human transcription machinery reveals the identity of the 7SK capping enzyme.","date":"2007","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/17643375","citation_count":367,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"25796446","id":"PMC_25796446","title":"Aerobic glycolysis tunes YAP/TAZ transcriptional activity.","date":"2015","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/25796446","citation_count":362,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21145461","id":"PMC_21145461","title":"Dynamics of cullin-RING ubiquitin ligase network revealed by systematic quantitative proteomics.","date":"2010","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/21145461","citation_count":318,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"23314748","id":"PMC_23314748","title":"Why do cellular proteins linked to K63-polyubiquitin chains not associate with proteasomes?","date":"2013","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/23314748","citation_count":213,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26618866","id":"PMC_26618866","title":"∆F508 CFTR interactome remodelling promotes rescue of cystic fibrosis.","date":"2015","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/26618866","citation_count":209,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"23403047","id":"PMC_23403047","title":"Defects of filaggrin-like proteins in both lesional and nonlesional atopic skin.","date":"2013","source":"The Journal of allergy and clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/23403047","citation_count":181,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"23455922","id":"PMC_23455922","title":"Interlaboratory reproducibility of large-scale human protein-complex analysis by standardized AP-MS.","date":"2013","source":"Nature methods","url":"https://pubmed.ncbi.nlm.nih.gov/23455922","citation_count":170,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16710414","id":"PMC_16710414","title":"The DNA sequence and biological annotation of human chromosome 1.","date":"2006","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/16710414","citation_count":144,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"36217030","id":"PMC_36217030","title":"A comprehensive SARS-CoV-2-human protein-protein interactome reveals COVID-19 pathobiology and potential host therapeutic targets.","date":"2022","source":"Nature biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/36217030","citation_count":140,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"27591049","id":"PMC_27591049","title":"SPATA2 Links CYLD to LUBAC, Activates CYLD, and Controls LUBAC Signaling.","date":"2016","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/27591049","citation_count":134,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"23376485","id":"PMC_23376485","title":"Proteomic analysis of podocyte exosome-enriched fraction from normal human urine.","date":"2013","source":"Journal of proteomics","url":"https://pubmed.ncbi.nlm.nih.gov/23376485","citation_count":126,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"35140242","id":"PMC_35140242","title":"Human transcription factor protein interaction networks.","date":"2022","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/35140242","citation_count":123,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"35013556","id":"PMC_35013556","title":"The ubiquitin-dependent ATPase p97 removes cytotoxic trapped PARP1 from chromatin.","date":"2022","source":"Nature cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/35013556","citation_count":122,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"25609649","id":"PMC_25609649","title":"Proteomic analyses reveal distinct chromatin-associated and soluble transcription factor complexes.","date":"2015","source":"Molecular systems biology","url":"https://pubmed.ncbi.nlm.nih.gov/25609649","citation_count":120,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21630459","id":"PMC_21630459","title":"Proteomic characterization of the human sperm nucleus.","date":"2011","source":"Proteomics","url":"https://pubmed.ncbi.nlm.nih.gov/21630459","citation_count":116,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"27545878","id":"PMC_27545878","title":"SPATA2-Mediated Binding of CYLD to HOIP Enables CYLD Recruitment to Signaling Complexes.","date":"2016","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/27545878","citation_count":115,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"30737378","id":"PMC_30737378","title":"The p300/YY1/miR-500a-5p/HDAC2 signalling axis regulates cell proliferation in human colorectal cancer.","date":"2019","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/30737378","citation_count":115,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21319273","id":"PMC_21319273","title":"An important role for CDK2 in G1 to S checkpoint activation and DNA damage response in human embryonic stem cells.","date":"2011","source":"Stem cells (Dayton, Ohio)","url":"https://pubmed.ncbi.nlm.nih.gov/21319273","citation_count":113,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26725010","id":"PMC_26725010","title":"KAP1 Recruitment of the 7SK snRNP Complex to Promoters Enables Transcription Elongation by RNA Polymerase II.","date":"2015","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/26725010","citation_count":113,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"28065597","id":"PMC_28065597","title":"A Global Analysis of the Receptor Tyrosine Kinase-Protein Phosphatase Interactome.","date":"2017","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/28065597","citation_count":102,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"35013218","id":"PMC_35013218","title":"EZH2 depletion potentiates MYC degradation inhibiting neuroblastoma and small cell carcinoma tumor formation.","date":"2022","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/35013218","citation_count":99,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"32908313","id":"PMC_32908313","title":"Targeting TRIM37-driven centrosome dysfunction in 17q23-amplified breast cancer.","date":"2020","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/32908313","citation_count":93,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"28977666","id":"PMC_28977666","title":"CHD3 and CHD4 form distinct NuRD complexes with different yet overlapping functionality.","date":"2017","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/28977666","citation_count":91,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"32814769","id":"PMC_32814769","title":"Histone methyltransferase DOT1L coordinates AR and MYC stability in prostate cancer.","date":"2020","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/32814769","citation_count":90,"is_preprint":false,"source_track":"gene2pubmed"}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":30747,"output_tokens":6393,"usd":0.094068},"stage2":{"model":"claude-opus-4-6","input_tokens":10101,"output_tokens":5028,"usd":0.264307},"total_usd":0.743777,"stage1_batch_id":"msgbatch_011rkcQdVV1RaFq9XhcG6df6","stage2_batch_id":"msgbatch_01RzgrJafdF4EWHhj5mNi6dh","note":"batch pricing = 50% of standard","round2_stage1":{"model":"claude-sonnet-4-6","input_tokens":43489,"output_tokens":9012,"usd":0.132824},"round2_rules_fired":"R3","round2_stage2":{"model":"claude-opus-4-6","input_tokens":13257,"output_tokens":4084,"usd":0.252578}},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2006,\n      \"finding\": \"Human and mouse S100A16 are homodimeric EF-hand Ca2+-binding proteins that bind two Ca2+ ions per dimer exclusively through the C-terminal EF-hand of each subunit; Ca2+ binding induces conformational changes and, in the human protein only, formation of a hydrophobic patch implicated in target protein recognition. The protein localizes to nucleoli and translocates to the cytoplasm in response to Ca2+ stimulation in glioblastoma cells.\",\n      \"method\": \"Recombinant protein purification, flow dialysis, Trp fluorescence, in situ hybridization, immunohistochemistry, live-cell imaging\",\n      \"journal\": \"The Journal of Biological Chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — biochemical reconstitution with purified recombinant protein, multiple orthogonal methods, functional structural characterization\",\n      \"pmids\": [\"17030513\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"NMR/X-ray structural characterization of homodimeric human S100A16 reveals that conformational rearrangement upon Ca2+ binding is minimal compared to other S100 proteins, attributable to the absence of a conserved glutamate at the end of the N-terminal EF-hand and to unusually strong hydrophobic interactions that stabilize the 'closed' form of the second EF-hand even in the Ca2+-bound state.\",\n      \"method\": \"X-ray crystallography, NMR spectroscopy (solution structure in apo and Ca2+-bound states)\",\n      \"journal\": \"Journal of Biological Inorganic Chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure plus NMR solution structure, consistent results in two states\",\n      \"pmids\": [\"21046186\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"S100A16 physically interacts with tumor suppressor p53; overexpression of S100A16 suppresses p53-responsive gene expression and promotes adipogenesis and preadipocyte proliferation in 3T3-L1 cells, while knockdown activates p53 targets and inhibits adipogenesis. Elevated intracellular Ca2+ via ionophores causes nuclear exclusion of S100A16.\",\n      \"method\": \"Co-immunoprecipitation, RNA interference, overexpression, Oil Red O staining, Western blot, Ca2+ ionophore treatment\",\n      \"journal\": \"Endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal Co-IP with functional follow-up, single lab\",\n      \"pmids\": [\"21266506\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"S100A14 physically interacts with S100A16 (identified by yeast two-hybrid and confirmed by co-immunoprecipitation and co-immunofluorescence); S100A14 overexpression post-transcriptionally upregulates S100A16 protein levels (no mRNA change), whereas S100A16 overexpression does not affect S100A14, indicating unidirectional regulation. This protein degradation is independent of classical proteasomal and lysosomal pathways.\",\n      \"method\": \"Yeast two-hybrid, co-immunoprecipitation, immunofluorescence, cycloheximide chase, retroviral overexpression/knockdown\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — Y2H plus reciprocal Co-IP, orthogonal localization confirmation, single lab\",\n      \"pmids\": [\"24086685\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"S100A16 promotes adipogenic differentiation of bone marrow-derived mesenchymal stem cells by increasing PPARγ promoter activity and decreasing RUNX2 promoter activity; loss of S100A16 enhances osteogenesis. JNK pathway is involved in S100A16-driven adipogenesis; ERK1/2 pathway is involved in osteogenesis.\",\n      \"method\": \"Overexpression/knockout in BM-MSCs, Oil Red O and Alizarin Red S staining, luciferase reporter assay, Western blot for ERK1/2 and JNK phosphorylation\",\n      \"journal\": \"Molecular biology reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — luciferase reporter plus functional differentiation assays, single lab\",\n      \"pmids\": [\"23526364\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"S100A16 overexpression in MCF-7 breast cancer cells upregulates Notch1, ZEB1, and ZEB2 transcription factors, leading to repression of E-cadherin and β-catenin and induction of N-cadherin and vimentin (EMT). Notch1 siRNA knockdown reverses S100A16-induced EMT, placing Notch1 downstream of S100A16.\",\n      \"method\": \"Retroviral overexpression, siRNA knockdown, Western blot, migration/invasion assays, epistasis experiment\",\n      \"journal\": \"Journal of Biomedical Science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — epistasis via siRNA rescue with multiple readouts, single lab\",\n      \"pmids\": [\"25287362\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"S100A16 overexpression in prostate cancer (DU-145) cells activates AKT and ERK signaling and downregulates p21 and p27; pharmacological inhibition of AKT (LY294002) or ERK (PD98059) attenuates S100A16-driven clone formation and invasion, placing AKT and ERK downstream of S100A16.\",\n      \"method\": \"Stable overexpression, shRNA knockdown, Western blot, kinase inhibitor epistasis, transwell/wound healing/colony formation assays\",\n      \"journal\": \"Tumour Biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — inhibitor epistasis with multiple functional readouts, single lab\",\n      \"pmids\": [\"27240591\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Brain microvascular endothelial cell (HBMEC) exosomes deliver signals that induce S100A16 upregulation and cytoplasm-to-nucleus translocation in recipient SCLC cells. Elevated S100A16 prevents mitochondrial membrane potential (Δψm) loss and enhances apoptosis resistance; this protective effect depends on prohibitin-1 (PHB-1) in the mitochondrial inner membrane, as PHB-1 siRNA abrogates the S100A16-mediated survival benefit.\",\n      \"method\": \"Exosome isolation by ultracentrifugation, GW4869 inhibitor, co-culture, Western blot, immunofluorescence, Annexin V/PI assay, JC-1 assay, siRNA knockdown\",\n      \"journal\": \"FASEB Journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — exosome functional experiments plus PHB-1 siRNA epistasis, single lab\",\n      \"pmids\": [\"30183374\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"S100A16 interacts with calmodulin (CaM) and regulates the CaM/CAMKK2/AMPK pathway to modulate hepatic lipid synthesis; S100A16 transgenic mice fed a high-fat diet show more severe fatty liver and higher triglycerides, while knockdown mice show the opposite, establishing a role for S100A16 in liver lipid metabolism via this pathway.\",\n      \"method\": \"Co-immunoprecipitation (CaM–S100A16), transgenic and knockdown mouse models, high-fat diet feeding, Western blot, Oil Red O staining\",\n      \"journal\": \"Journal of Cellular Physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — Co-IP identifying binding partner plus in vivo genetic models with defined readouts, single lab\",\n      \"pmids\": [\"31069793\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"S100A16 interacts with myosin-9 (identified by mass spectrometry and Co-IP) during TGF-β stimulation or kidney injury; this interaction promotes cytoskeletal F-actin reorganization and epithelial-mesenchymal transition in renal tubular (HK-2) cells, driving tubulointerstitial fibrosis in UUO mouse model.\",\n      \"method\": \"Mass spectrometry screening of binding partners, co-immunoprecipitation, immunofluorescence (F-actin), S100A16 overexpression/knockdown in HK-2 cells, UUO mouse model with S100A16Tg and S100A16+/- mice\",\n      \"journal\": \"Cell Death & Disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — MS identification plus Co-IP of binding partner with in vivo genetic validation, single lab\",\n      \"pmids\": [\"32094322\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"S100A16 promotes EMT and metastasis in pancreatic ductal adenocarcinoma cells by upregulating TWIST1 and activating STAT3 signaling; S100A16 knockdown combined with gemcitabine shows synergistic anti-tumor effects in vitro and in vivo.\",\n      \"method\": \"shRNA knockdown, overexpression, Western blot (TWIST1, p-STAT3), in vitro invasion/migration assays, xenograft mouse model\",\n      \"journal\": \"Biochemical Pharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vitro and in vivo experiments with defined pathway markers, single lab\",\n      \"pmids\": [\"33359364\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"S100A16 physically interacts with GRP78 (confirmed by Co-IP) predominantly in the ER of HK-2 cells; S100A16 overexpression drives GRP78 and S100A16 co-localization into the cytoplasm. S100A16 and IRE1α compete for GRP78 binding; displacement of GRP78 by S100A16 releases IRE1α, which is then phosphorylated and splices XBP1, activating ER stress. Ca2+ chelation (BAPTA-AM) blunts this pathway and the associated fibrosis gene upregulation.\",\n      \"method\": \"Co-immunoprecipitation (competitive binding assay), immunofluorescence, lentiviral overexpression, BAPTA-AM treatment, Western blot (p-IRE1α, XBP1s, GRP78)\",\n      \"journal\": \"Cell Death & Disease\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1/2 — Co-IP competitive binding, localization by immunofluorescence, Ca2+ chelation mechanistic test; multiple orthogonal methods in single study\",\n      \"pmids\": [\"34645789\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"S100A16 promotes pancreatic cancer (PDAC) cell proliferation, migration, and invasion via FGF19-mediated activation of AKT and ERK1/2 signaling; S100A16 knockdown induces G2/M arrest and apoptosis. FGF19 dependence was demonstrated by showing that S100A16 effects on AKT/ERK1/2 require FGF19.\",\n      \"method\": \"shRNA knockdown, overexpression, Western blot, flow cytometry (cell cycle/apoptosis), transwell assay, in vivo xenograft\",\n      \"journal\": \"Cell Biology and Toxicology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vitro and in vivo functional experiments with FGF19 epistasis, single lab\",\n      \"pmids\": [\"33389337\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"S100A16 promotes Wnt/β-catenin signaling in renal interstitial fibroblasts during acute kidney injury by facilitating HRD1 E3 ubiquitin ligase-mediated ubiquitination and proteasomal degradation of GSK3β and CK1α (negative regulators of β-catenin); S100A16 knockout mice show impaired Wnt/β-catenin activation and restored HGF expression after ischemia-reperfusion injury.\",\n      \"method\": \"S100A16 knockout mice (IRI model), S100A16 overexpression in NRK-49F fibroblasts, Western blot, ubiquitination assay, ICG-001 pathway inhibitor, hypoxia/reoxygenation model\",\n      \"journal\": \"Cellular and Molecular Life Sciences\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1/2 — in vivo genetic KO plus in vitro mechanistic ubiquitination assay with inhibitor epistasis; multiple orthogonal approaches\",\n      \"pmids\": [\"35279748\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"S100A16 deficiency prevents hepatic stellate cell (HSC) activation and liver fibrosis by a mechanism in which S100A16 binds p53 to induce its degradation, thereby augmenting CXCR4 expression, which activates ERK1/2 and AKT signaling to promote HSC activation. S100a16 transgenic mice develop spontaneous liver fibrosis, while S100a16 knockout mice are protected.\",\n      \"method\": \"Co-immunoprecipitation (S100A16–p53), S100a16 knockout and transgenic mice, CCl4/bile duct ligation fibrosis models, RNA sequencing, HSC isolation, Western blot\",\n      \"journal\": \"Metabolism: Clinical and Experimental\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal Co-IP for binding partner, in vivo genetic models (KO + TG) with spontaneous phenotype, transcriptomic identification of CXCR4 as downstream effector\",\n      \"pmids\": [\"35914619\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"S100A16 physically interacts with DEPDC1 (confirmed by Co-IP); S100A16 promotes nephroblastoma cell proliferation, invasion, migration, and angiogenesis through the PI3K/Akt/mTOR pathway, and DEPDC1 overexpression partially rescues the effects of S100A16 knockdown.\",\n      \"method\": \"Co-immunoprecipitation, CCK-8, Transwell, tube formation assay, Western blot (PI3K/Akt/mTOR), siRNA knockdown and overexpression\",\n      \"journal\": \"Polish Journal of Pathology\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — single Co-IP without mutagenesis; single lab, single study\",\n      \"pmids\": [\"37955537\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"S100A16 promotes liver lipid accumulation (lipogenesis) and the S100a16 deletion protects mice from alcohol-induced fatty liver by a mechanism involving upregulation of MANF (mesencephalic astrocyte-derived neurotrophic factor), which inhibits ER stress; MANF silencing reverses the lipid-protective effect of S100a16 knockout, establishing MANF as a downstream effector.\",\n      \"method\": \"S100a16 knockout and transgenic mice (Gao-binge model), primary hepatocytes, MANF siRNA epistasis, Western blot\",\n      \"journal\": \"International Journal of Biological Sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vivo genetic models plus siRNA epistasis identifying MANF as downstream, single lab\",\n      \"pmids\": [\"37928262\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"TFAP2B is identified as a transcription factor that directly drives S100A16 expression (confirmed by ChIP and luciferase reporter assays); HIF-1α transcriptionally upregulates HRD1 (confirmed by ChIP and luciferase reporter), operating within the S100A16-HRD1-GSK3β/CK1α pathway during renal hypoxia/ischemia-reperfusion injury.\",\n      \"method\": \"ChIP assay, luciferase reporter assay, S100A16 knockout NRK-52E cells, HIF-1α inhibitor, overexpression of HIF-1α and TFAP2B, Western blot\",\n      \"journal\": \"Cell Death & Disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP and luciferase reporter confirm direct transcription factor binding at promoters, single lab\",\n      \"pmids\": [\"38710691\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"VDAC1 upregulates NF-κB/p65, which binds the S100A16 promoter to transcriptionally activate S100A16 in cardiomyocytes following ischemia/reperfusion injury; S100A16 then interacts with calmodulin (CaM) and dysregulates the CaM/CAMKK2/AMPK pathway, causing oxidative stress and inflammatory injury. Adenovirus-mediated S100A16 inhibition reduces infarct size and cardiomyocyte apoptosis.\",\n      \"method\": \"Ligation/release I/R mouse model, hypoxia/reoxygenation in vitro, adenoviral S100A16 inhibition, NF-κB/p65 binding to S100A16 promoter, Western blot, ROS measurement, flow cytometry\",\n      \"journal\": \"European Journal of Pharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vivo and in vitro models with promoter-binding evidence and defined downstream pathway, single lab\",\n      \"pmids\": [\"39613175\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"SPDEF transcription factor directly upregulates S100A16 transcription in pancreatic adenocarcinoma cells, and S100A16 in turn activates the PI3K/AKT signaling pathway to promote cell migration, proliferation, and invasion.\",\n      \"method\": \"TCGA data analysis, in vitro overexpression/knockdown, Western blot, dual-luciferase reporter assay, transwell assay\",\n      \"journal\": \"Biomolecules & Biomedicine\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — single lab, mechanistic follow-up partial; luciferase assay suggests transcriptional regulation but no ChIP validation\",\n      \"pmids\": [\"38520747\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"S100A16 binds MOV10 RNA helicase (confirmed by co-immunoprecipitation) in lung adenocarcinoma cells and positively regulates MOV10 expression; MOV10 in turn binds and stabilizes ITGA3 mRNA (confirmed by RNA immunoprecipitation and actinomycin D mRNA stability assay), thereby maintaining ECM-receptor interaction signaling and promoting malignant cell phenotypes.\",\n      \"method\": \"Co-immunoprecipitation (S100A16–MOV10), RNA immunoprecipitation (MOV10–ITGA3 mRNA), actinomycin D mRNA stability assay, shRNA knockdown, Western blot\",\n      \"journal\": \"Molecular Medicine Reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — protein–protein Co-IP and protein–mRNA RIP with mRNA stability assay; multiple orthogonal methods, single lab\",\n      \"pmids\": [\"39450567\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"S100A16 knockdown in cervical cancer (HeLa, SiHa) cells reduces RPN2 (ribophorin II) expression via p-STAT3; reduced RPN2 decreases phospho-GSK3β levels, which limits β-catenin nuclear translocation and TCF-mediated transcription, suppressing cell migration. Fractionation confirmed reduced nuclear β-catenin upon S100A16 silencing.\",\n      \"method\": \"RNA sequencing after S100A16 siRNA, Western blot, nuclear/cytosolic fractionation, RPN2 siRNA and S100A16 rescue experiments\",\n      \"journal\": \"Biochimica et Biophysica Acta – Molecular Cell Research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — RNA-seq pathway discovery plus rescue epistasis and subcellular fractionation; single lab\",\n      \"pmids\": [\"40907797\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"S100A16 is enriched in the nucleoli of metastatic breast cancer cells; ChIP-MS shows S100A16 associates with rDNA loci together with RPA194 (catalytic subunit of RNA Pol I); loss of S100A16 disrupts RNA Pol I activation and rRNA synthesis, reverses EMT, inhibits invasion, and reduces metastatic incidence in animal models.\",\n      \"method\": \"Nucleolar proteomics (quantitative), ChIP-MS (rDNA loci), RNA Pol I activity assay, S100A16 knockdown/overexpression, in vivo metastasis mouse model\",\n      \"journal\": \"Cell Death & Disease\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1/2 — ChIP-MS for chromatin/protein association at rDNA plus functional RNA Pol I assay and in vivo metastasis validation; multiple orthogonal methods\",\n      \"pmids\": [\"40846689\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"S100A14 stabilizes S100A16 protein via post-translational modification (confirmed by co-immunoprecipitation and CHX chase assay, without transcriptional change); the S100A14/S100A16 complex suppresses p53 protein stability and transcriptional activity (including p21 expression), promoting pancreatic cancer proliferation, invasion, and EMT. S100A14 knockdown abrogates the S100A16-mediated p53 suppression.\",\n      \"method\": \"Co-immunoprecipitation (S100A14–S100A16), CHX chase (protein stability), dual-luciferase assay (p53 transcriptional activity), Western blot, siRNA epistasis\",\n      \"journal\": \"Oncology Research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — Co-IP and CHX stability assay with dual-luciferase for transcriptional output; single lab\",\n      \"pmids\": [\"41799516\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"S100A16 is a homodimeric EF-hand Ca2+-binding protein that senses Ca2+ through its C-terminal EF-hand and undergoes Ca2+-dependent nuclear-to-cytoplasmic translocation; in the nucleus it associates with rDNA/RNA Pol I to drive rRNA biogenesis and metastasis, while in the cytoplasm it interacts with binding partners including p53 (promoting its degradation), GRP78 (releasing IRE1α to activate ER stress via IRE1α/XBP1), myosin-9 (reorganizing the cytoskeleton during EMT), calmodulin (modulating CaM/CAMKK2/AMPK signaling in metabolism and cardiac injury), and HRD1 (facilitating ubiquitin-mediated degradation of GSK3β and CK1α to activate Wnt/β-catenin); upstream, its transcription is driven by TFAP2B and NF-κB/p65, and downstream it activates PI3K/AKT, ERK1/2, STAT3, and Notch1 pathways to promote proliferation, adipogenesis, EMT, and survival in diverse tissue contexts.\"\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2006,\n      \"finding\": \"S100A16 is a homodimeric EF-hand Ca²⁺-binding protein that binds two Ca²⁺ ions per dimer exclusively via the C-terminal EF-hand of each subunit (the N-terminal EF-hand lacks the conserved glutamate and is non-functional). Ca²⁺ binding induces conformational changes detected by Trp fluorescence, and in human S100A16 (but not mouse) a hydrophobic patch implicated in target-protein recognition is formed upon Ca²⁺ binding. In glioblastoma cells S100A16 accumulates in nucleoli and translocates to the cytoplasm upon Ca²⁺ stimulation.\",\n      \"method\": \"Recombinant protein purification, flow dialysis (Ca²⁺ binding stoichiometry/affinity), Trp fluorescence spectroscopy, in situ hybridization, immunohistochemistry, immunofluorescence localization\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal biochemical methods (flow dialysis, fluorescence, structural) in a single foundational paper; replicated biochemically by structural study PMID:21046186\",\n      \"pmids\": [\"17030513\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"The homodimeric structure of human S100A16 was determined both in the apo and Ca²⁺-bound states by NMR and X-ray crystallography. Unlike most S100 proteins, the conformational rearrangement upon Ca²⁺ binding is minor, attributable to the absence of the glutamate residue at the end of the N-terminal EF-hand and to unusually strong hydrophobic interactions between helices 3 and 4 that stabilize the 'closed' conformation of the second EF-hand even after Ca²⁺ binding.\",\n      \"method\": \"NMR solution structure (apo and Ca²⁺-bound), X-ray crystallography (solid state); structures compared to functional Ca²⁺-binding data\",\n      \"journal\": \"Journal of biological inorganic chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — dual structural determination (NMR + crystal) with mechanistic interpretation of low Ca²⁺ affinity\",\n      \"pmids\": [\"21046186\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"S100A16 promotes adipogenesis and preadipocyte proliferation: overexpression in 3T3-L1 cells markedly enhances differentiation into adipocytes while reducing insulin-stimulated glucose uptake and AKT phosphorylation; siRNA knockdown inhibits adipogenesis. Immunoprecipitation showed S100A16 physically interacts with the tumor suppressor p53; S100A16 overexpression suppresses p53-responsive genes and knockdown activates them. Elevation of intracellular Ca²⁺ via ionophore causes nuclear exclusion of S100A16.\",\n      \"method\": \"Overexpression and RNAi in 3T3-L1 preadipocytes; Oil Red O staining; glucose uptake assay; AKT phosphorylation Western blot; co-immunoprecipitation (S100A16–p53); Ca²⁺ ionophore treatment with localization imaging\",\n      \"journal\": \"Endocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal functional assays plus co-IP interaction; replicated in subsequent studies\",\n      \"pmids\": [\"21266506\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"High-calcium diet reduces nuclear S100A16 levels in 3T3-L1 preadipocytes (Ca²⁺ ionophore-induced nuclear exclusion), correlating with inhibition of adipogenesis and enhanced insulin sensitivity, demonstrating that Ca²⁺-driven cytoplasmic translocation of S100A16 is the mechanistic link between dietary calcium and adipogenesis suppression.\",\n      \"method\": \"Obese rat model; Western blot for S100A16 expression; 3T3-L1 preadipocyte Ca²⁺ ionophore treatment with subcellular localization; Oil Red O staining; AKT phosphorylation\",\n      \"journal\": \"Metabolism: clinical and experimental\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2/3 — consistent with prior 3T3-L1 data but in vivo correlation plus in vitro mechanistic follow-up is single-lab\",\n      \"pmids\": [\"21871643\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"S100A16 physically interacts with S100A14 as identified by yeast two-hybrid screen and confirmed by co-immunoprecipitation and double immunofluorescence. S100A14 overexpression leads to post-transcriptional upregulation of S100A16 protein (no change in mRNA), while S100A16 overexpression does not reciprocally upregulate S100A14, establishing a unidirectional regulatory relationship. Protein degradation of both S100A14 and S100A16 is independent of proteasomal and lysosomal pathways.\",\n      \"method\": \"Yeast two-hybrid screen; co-immunoprecipitation; double indirect immunofluorescence; cycloheximide chase assay; proteasome/lysosome inhibitor experiments; qRT-PCR and Western blot\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — interaction identified by Y2H and confirmed by reciprocal Co-IP and imaging; post-transcriptional regulation confirmed by mRNA/protein discordance\",\n      \"pmids\": [\"24086685\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"In bone marrow-derived mesenchymal stem cells (BM-MSCs), S100A16 overexpression stimulates adipogenesis and inhibits osteogenesis: it increases PPARγ promoter activity and decreases RUNX2 promoter activity. The ERK1/2 pathway mediates osteogenesis regulation whereas the JNK pathway mediates adipogenesis regulation by S100A16.\",\n      \"method\": \"S100A16 transgenic and knockout BM-MSCs; Oil Red O and Alizarin Red S staining; luciferase reporter assays (PPARγ and RUNX2 promoters); Western blot for p-ERK1/2 and p-JNK; RT-PCR for BMP2, RUNX2, PPARγ, C/EBPα\",\n      \"journal\": \"Molecular biology reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — luciferase reporter + pathway Western blots, single-lab study\",\n      \"pmids\": [\"23526364\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"S100A16 overexpression in MCF-7 breast cancer cells upregulates Notch1, ZEB1, and ZEB2, which repress E-cadherin and β-catenin and increase N-cadherin and vimentin (EMT markers). Notch1 siRNA knockdown reverses the EMT induced by S100A16 overexpression, placing Notch1 as a critical downstream effector of S100A16-driven EMT.\",\n      \"method\": \"Retroviral overexpression in MCF-7; siRNA knockdown of Notch1; Western blot and qRT-PCR for EMT markers; proliferation, colony formation, migration, and invasion assays\",\n      \"journal\": \"Journal of biomedical science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2/3 — epistasis established by siRNA rescue; single-lab with multiple phenotypic readouts\",\n      \"pmids\": [\"25287362\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Estrogen (E2) suppresses adipogenesis by inhibiting S100A16 expression; luciferase assay showed E2 directly inhibits the S100A16 promoter. Overexpression of S100A16 reversed E2-induced inhibition of adipogenesis, placing S100A16 downstream of estrogen signaling in adipogenic regulation.\",\n      \"method\": \"Ovariectomized rat model; mouse embryonic fibroblast adipogenesis assay; luciferase reporter assay (S100A16 promoter); S100A16 overexpression rescue experiment; Western blot for PPARγ, aP2, C/EBPα, S100A16\",\n      \"journal\": \"Journal of molecular endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — promoter luciferase + genetic rescue experiment; single lab\",\n      \"pmids\": [\"24501224\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"In oral squamous cell carcinoma (OSCC), S100A16 overexpression promotes differentiation and acts as a tumor suppressor: it reduces cell proliferation, sphere formation, 3D-invasive ability, and tumorigenesis in a mouse xenograft model. Mechanistically, S100A16 overexpression downregulates self-renewal markers Bmi-1 and Oct4A and invasion-related MMP1 and MMP9, while knockdown has opposite effects.\",\n      \"method\": \"Retroviral overexpression and knockdown in CaLH3 and H357 cells; proliferation, sphere formation, 3D organotypic invasion assays; mouse xenograft model; Western blot and qRT-PCR for differentiation, self-renewal, and invasion markers\",\n      \"journal\": \"BMC cancer\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal in vitro assays plus in vivo xenograft validation; both gain- and loss-of-function\",\n      \"pmids\": [\"26353754\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"S100A16 promotes prostate cancer cell invasion, migration, and proliferation via activation of AKT and ERK signaling pathways and downstream downregulation of tumor suppressors p21 and p27. Specific inhibitors of AKT (LY294002) and ERK (PD98059) suppressed the S100A16-induced clone formation and invasion, functionally confirming pathway placement.\",\n      \"method\": \"Stable overexpression and shRNA knockdown in DU-145/PC-3 cells; Transwell invasion/migration, wound healing, colony formation; Western blot for p-AKT, p-ERK, p21, p27; pharmacological pathway inhibition\",\n      \"journal\": \"Tumour biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2/3 — pharmacological epistasis plus gain/loss-of-function; single lab\",\n      \"pmids\": [\"27240591\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Brain microvascular endothelial cell (HBMEC) exosomes transfer S100A16 protein to SCLC cells, inducing its elevation and translocation from the cytoplasm to the nucleus. Elevated S100A16 in SCLC cells prevents loss of mitochondrial membrane potential (Δψm) and confers resistance to apoptosis under stress. This protective effect depends on prohibitin (PHB)-1, a mitochondrial inner membrane protein: PHB-1 siRNA knockdown in S100A16-overexpressing cells abolishes the protective phenotype, placing PHB-1 downstream of S100A16 in mitochondrial protection.\",\n      \"method\": \"Co-culture with HBMEC; GW4869 exosome-release inhibition; ultracentrifugation-purified exosome treatment; Western blot and immunofluorescence for S100A16 localization; Annexin V/PI apoptosis assay; JC-1 mitochondrial membrane potential assay; PHB-1 siRNA epistasis\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal functional assays plus epistasis via PHB-1 siRNA; exosome mechanism confirmed by inhibitor control\",\n      \"pmids\": [\"30183374\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"In cancer stem-like spheroid cells from Yumoto cervical carcinoma, S100A16 positively regulates the stem cell transcription factors Oct4 and Nanog at the protein level. S100A16 knockdown decreases Oct4 and Nanog protein and reduces spheroid size. The proteasome inhibitor lactacystin blocks the S100A16-knockdown-induced decrease of Oct4/Nanog protein, indicating that S100A16 normally suppresses proteasomal degradation of p53 (which in turn represses Oct4/Nanog).\",\n      \"method\": \"Sphere formation assay; siRNA knockdown of S100A16; RT-PCR and Western blot for Oct4, Nanog, p53, S100A16; proteasome inhibitor lactacystin treatment\",\n      \"journal\": \"Oncology letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — mechanistic inference from inhibitor experiment; single lab, single cell line\",\n      \"pmids\": [\"29928366\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"S100A16 interacts with calmodulin (CaM) and through this interaction regulates the AMPK signaling pathway (CaM/CAMKK2/AMPK) to promote hepatic lipid synthesis. S100A16 transgenic mice on high-fat diet develop significantly more severe fatty liver than wild-type, while knockdown mice are protected, confirming in vivo lipogenic function.\",\n      \"method\": \"S100A16 transgenic and knockdown C57BL/6 mice on HFD/NFD; serum TG and liver histology; co-immunoprecipitation (S100A16–calmodulin); RNA sequencing; Western blot for AMPK pathway proteins\",\n      \"journal\": \"Journal of cellular physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — co-IP interaction plus in vivo genetic models; single lab\",\n      \"pmids\": [\"31069793\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"In bladder cancer chemoresistance, S100A16 expression is transcriptionally regulated by the EMT transcription factor Snail. S100A16 knockdown suppresses the AKT/Bcl-2 pathway, promotes apoptosis, and resensitizes mitomycin-C-resistant cells to the drug, placing S100A16 in a Snail → S100A16 → AKT/Bcl-2 anti-apoptosis axis.\",\n      \"method\": \"Proteomics of drug-resistant cell line (LC-MS/MS); RT-PCR and Western blot confirmation; siRNA knockdown of S100A16; CCK8 chemosensitivity assay; Western blot for AKT, Bcl-2, EMT markers\",\n      \"journal\": \"Cancer management and research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2/3 — proteomics discovery plus functional siRNA validation; single lab\",\n      \"pmids\": [\"31118765\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"S100A16 interacts with myosin-9 in response to elevated Ca²⁺ and TGF-β stimulation in renal tubular (HK-2) cells, promoting cytoskeletal reorganization (F-actin remodeling) and EMT progression during renal tubulointerstitial fibrosis. S100A16 transgenic mice subjected to unilateral ureteral obstruction (UUO) show exacerbated fibrosis compared to heterozygous knockout mice.\",\n      \"method\": \"Mass spectrometry pulldown to identify S100A16 binding partners; UUO mouse model with S100A16 transgenic and knockout mice; immunohistochemistry; Western blot for EMT and fibrosis markers; F-actin immunofluorescence in S100A16 OE/KD HK-2 cells; Ca²⁺ stimulation experiments\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — MS-based interactor identification confirmed in genetic mouse models with multiple functional readouts\",\n      \"pmids\": [\"32094322\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"In pancreatic ductal adenocarcinoma (PDAC), S100A16 induces EMT via enhanced expression of TWIST1 and activation of the STAT3 signaling pathway, promoting metastasis in vitro and in vivo. Combination of S100A16 downregulation with gemcitabine shows synergistic antitumor effects.\",\n      \"method\": \"In vitro knockdown/overexpression in PDAC cell lines; in vivo xenograft; Western blot for TWIST1, STAT3 activation, and EMT markers; GEO/TCGA database correlation analysis\",\n      \"journal\": \"Biochemical pharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2/3 — in vivo plus in vitro functional data; mechanism via TWIST1/STAT3 supported by Western blot but no direct promoter or rescue experiments\",\n      \"pmids\": [\"33359364\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"S100A16 physically interacts with GRP78 (an ER chaperone and master regulator of ER stress) in HK-2 renal tubular cells, with colocalization occurring primarily in the ER under normal conditions. S100A16 overexpression causes GRP78 to translocate into the cytoplasm where it competes with IRE1α for GRP78 binding. Freed IRE1α becomes phosphorylated, leading to XBP1 splicing and ER stress activation. Ca²⁺ chelation with BAPTA-AM suppresses cytoplasmic colocalization of S100A16 and GRP78 and blocks downstream ER stress and fibrosis gene induction.\",\n      \"method\": \"Co-immunoprecipitation (S100A16–GRP78, competitive binding with IRE1α); immunofluorescence colocalization; Lenti-S100A16 overexpression; UUO mouse model; Western blot for ER stress markers (GRP78, p-IRE1α, XBP1s); BAPTA-AM Ca²⁺ chelation experiment\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — co-IP confirmed interaction, competitive binding shown, Ca²⁺ dependence demonstrated, in vivo model corroborates\",\n      \"pmids\": [\"34645789\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"S100A16 promotes pancreatic cancer cell proliferation, migration, invasion, and metastasis via AKT and ERK1/2 signaling in a fibroblast growth factor 19 (FGF19)-dependent manner. S100A16 knockdown induces G2/M cell cycle arrest and apoptosis in PDAC cells.\",\n      \"method\": \"siRNA knockdown and overexpression in PDAC cell lines; in vivo metastasis model; Western blot for AKT, ERK1/2 activation; flow cytometry for cell cycle and apoptosis; FGF19 dependency validated by rescue experiments\",\n      \"journal\": \"Cell biology and toxicology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2/3 — FGF19-dependent pathway placement supported by rescue, single lab\",\n      \"pmids\": [\"33389337\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"In gastric cancer cells, S100A16 promotes EMT, invasion, and migration via ZO-2 (Zonula Occludens-2) ubiquitination and degradation. Proteomic analysis identified ZO-2 as an S100A16 interacting protein; excessive S100A16 causes ZO-2 loss through ubiquitin-mediated degradation.\",\n      \"method\": \"Proteomic interactome analysis; co-IP; ubiquitination assay; Western blot for ZO-2, EMT markers; in vivo and in vitro proliferation and migration assays\",\n      \"journal\": \"Frontiers in cell and developmental biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2/3 — proteomics-identified interaction confirmed by co-IP; ubiquitination mechanism via single-lab assay\",\n      \"pmids\": [\"34650982\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"ADAMTS19 suppresses gastric cancer cell migration and invasion by binding cytoplasmic P65 (NF-κB), reducing nuclear P65 phosphorylation, and thereby downregulating S100A16 transcription. Overexpression of S100A16 reverses the migration/invasion suppression by ADAMTS19, placing S100A16 as a direct downstream transcriptional target of the NF-κB pathway in gastric cancer.\",\n      \"method\": \"Co-immunoprecipitation (ADAMTS19–P65); immunofluorescence; dual-luciferase reporter for NF-κB/S100A16; gain- and loss-of-function assays; S100A16 rescue experiments\",\n      \"journal\": \"Biomolecules\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — co-IP plus luciferase reporter epistasis; single lab\",\n      \"pmids\": [\"33921267\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"S100A16 promotes acute kidney injury (AKI) by activating the E3 ubiquitin ligase HRD1, which ubiquitinates and degrades the Wnt/β-catenin pathway negative regulators GSK3β and CK1α, thereby activating β-catenin signaling and inhibiting HGF secretion. S100A16 knockout in mice subjected to ischemia-reperfusion injury impeded Wnt/β-catenin activation and rescued HGF expression.\",\n      \"method\": \"S100A16 knockout mice + ischemia-reperfusion injury model; NRK-49F renal fibroblast overexpression/knockdown; Western blot for HRD1, GSK3β, CK1α, β-catenin, HGF; ubiquitination assays; ICG-001 (Wnt inhibitor) epistasis\",\n      \"journal\": \"Cellular and molecular life sciences\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo genetic model + ubiquitination mechanism + pharmacological epistasis, multiple orthogonal methods\",\n      \"pmids\": [\"35279748\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"S100A16 deficiency prevents hepatic stellate cell (HSC) activation and liver fibrosis. Mechanistically, S100A16 binds p53 protein and promotes its degradation; reduced p53 leads to increased CXCR4 expression, which activates ERK1/2 and AKT signaling to drive HSC activation. S100a16 transgenic mice develop spontaneous liver fibrosis, confirming gain-of-function pro-fibrotic activity.\",\n      \"method\": \"S100a16 knockout and transgenic mice in multiple liver fibrosis models; HSC isolation; RNA sequencing; co-IP (S100A16–p53); Western blot for CXCR4, p-ERK1/2, p-AKT; S100a16 genetic silencing in HSCs\",\n      \"journal\": \"Metabolism: clinical and experimental\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo genetic models (KO + Tg) + RNA-seq + co-IP mechanism; strong preponderance\",\n      \"pmids\": [\"35914619\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Downregulation of S100A16 (together with HSP27) in placenta-derived multipotent cells (PDMCs) is sufficient to drive differentiation into functional astrocytes without chemical induction. Co-silencing S100A16 and HSP27 produces cells with classical astrocytic morphology, expression of astrocyte markers, and functional electrophysiology and Ca²⁺ influx characteristics.\",\n      \"method\": \"siRNA co-silencing of S100A16 and HSP27; immunofluorescence for neural/astrocyte markers; electrophysiology; Ca²⁺ influx assay; morphology imaging\",\n      \"journal\": \"Stem cell reviews and reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2/3 — functional differentiation with multiple validation methods but mechanistic pathway not resolved; single lab\",\n      \"pmids\": [\"35061207\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"HIF-1α transcriptionally upregulates HRD1 by binding to the HRD1 promoter (confirmed by ChIP and luciferase assay) within the S100A16-HRD1-GSK3β/CK1α signaling axis in renal hypoxia injury. The transcription factor TFAP2B was identified as a direct transcriptional activator of S100A16 (confirmed by ChIP and luciferase reporter assay), placing TFAP2B upstream of S100A16 in the hypoxic kidney injury pathway.\",\n      \"method\": \"Chromatin immunoprecipitation (ChIP) for HIF-1α at HRD1 promoter and TFAP2B at S100A16 promoter; luciferase reporter assays; S100A16 knockout rat tubular epithelial cells (NRK-52E); hypoxia/reoxygenation model; IRI mouse model; Western blot\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — ChIP + luciferase reporter confirm transcriptional regulation; in vivo and in vitro models with genetic KO\",\n      \"pmids\": [\"38710691\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"S100A16 binds to the RNA helicase MOV10 (confirmed by co-immunoprecipitation) and positively modulates MOV10 expression in lung adenocarcinoma cells. MOV10 in turn binds ITGA3 mRNA (confirmed by RNA immunoprecipitation) and stabilizes it (confirmed by actinomycin D chase assay), thereby activating ECM-receptor interaction pathways to promote LUAD malignant progression.\",\n      \"method\": \"Co-immunoprecipitation (S100A16–MOV10); RNA immunoprecipitation (MOV10–ITGA3 mRNA); actinomycin D mRNA stability assay; siRNA knockdown; Western blot; proliferation, migration, invasion, angiogenesis assays\",\n      \"journal\": \"Molecular medicine reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — co-IP + RIP + mRNA stability assay; single lab but multiple orthogonal methods\",\n      \"pmids\": [\"39450567\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"VDAC1 upregulates NF-κB/p65 signaling after myocardial ischemia/reperfusion injury, and NF-κB/p65 binds the S100A16 promoter to transcriptionally activate S100A16 expression. Elevated S100A16 then interacts with calmodulin (CaM) in a Ca²⁺-dependent manner to dysregulate the CaMKK2/AMPK pathway, contributing to cardiomyocyte apoptosis, inflammation, and ROS production. Adenovirus-mediated S100A16 inhibition reduced infarct size and improved cardiac function.\",\n      \"method\": \"Left anterior descending artery ligation/release in vivo; cardiomyocyte H/R model; Western blot for VDAC1, p-NF-κB/p65, S100A16, CaMKK2, AMPK; NF-κB/p65 promoter binding (ChIP implied); S100A16–CaM co-interaction; adenovirus-mediated S100A16 knockdown; cardiac function (echocardiography); flow cytometry for apoptosis/ROS\",\n      \"journal\": \"European journal of pharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2/3 — in vivo model + Ca²⁺-CaM interaction + pathway Western blots; CaM interaction inferred functionally; single lab\",\n      \"pmids\": [\"39613175\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"SPDEF transcription factor enhances transcription of S100A16, which in turn activates the PI3K/AKT signaling pathway to promote pancreatic adenocarcinoma cell migration, proliferation, and invasion. S100A16 was identified as one of four key SPDEF-regulated genes by integrative genomic analysis.\",\n      \"method\": \"TCGA database mining; in vitro overexpression/knockdown; Western blot for PI3K/AKT activation; qRT-PCR; proliferation and invasion assays; SPDEF–S100A16 transcriptional correlation\",\n      \"journal\": \"Biomolecules & biomedicine\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3/4 — transcriptional regulation inferred from expression correlation and functional assays; no direct promoter binding confirmed\",\n      \"pmids\": [\"38520747\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"S100A16 knockdown in HeLa and SiHa cervical cancer cells inhibits migration without affecting viability. RNA sequencing revealed S100A16 transcriptionally regulates Ribophorin II (RPN2); S100A16 silencing decreases RPN2 through reduced p-STAT3, which in turn decreases p-GSK3β and prevents nuclear translocation of β-catenin, suppressing the β-catenin/TCF pathway and cell migration.\",\n      \"method\": \"S100A16 siRNA knockdown; RNA sequencing; Western blot for RPN2, p-STAT3, p-GSK3β, β-catenin; nuclear/cytosolic fractionation; cell migration assay; RPN2 overexpression rescue\",\n      \"journal\": \"Biochimica et biophysica acta. Molecular cell research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2/3 — RNA-seq pathway discovery + rescue experiment + fractionation; single lab\",\n      \"pmids\": [\"40907797\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"S100A16 localizes to the nucleolus of metastatic breast cancer cells and associates with RNA Polymerase I (RPA194, the catalytic subunit of Pol I) at rDNA loci (detected by ChIP-MS). Loss of S100A16 disrupts RNA Polymerase I activation and rRNA synthesis, reverses EMT, inhibits invasion, and reduces metastatic incidence in animal models.\",\n      \"method\": \"Nucleolar proteomics from primary vs. metastatic breast cancer cell lines; ChIP-MS (S100A16 at rDNA with RPA194); S100A16 loss-of-function (siRNA/CRISPR); rRNA synthesis assay; EMT marker Western blot; invasion assay; in vivo metastasis model\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — ChIP-MS confirms rDNA association with Pol I; functional rRNA synthesis assay; in vivo validation; multiple orthogonal methods\",\n      \"pmids\": [\"40846689\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"S100A14 stabilizes S100A16 protein through post-translational modification (not transcriptional regulation), and the S100A14/S100A16 complex reduces p53 protein stability and inhibits p53 transcriptional activity and downstream p21 expression, promoting pancreatic cancer progression. Co-IP confirmed the S100A14–S100A16 protein interaction; CHX chase assay demonstrated S100A14-dependent S100A16 protein stabilization.\",\n      \"method\": \"Co-immunoprecipitation (S100A14–S100A16); cycloheximide (CHX) chase assay for protein stability; dual-luciferase assay for p53 transcriptional activity; siRNA knockdown; Western blot for p53, p21, EMT markers; CCK-8 and Transwell assays\",\n      \"journal\": \"Oncology research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — co-IP + CHX chase + luciferase reporter confirm post-translational stabilization and p53 suppression; single lab\",\n      \"pmids\": [\"41799516\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"S100A16 is a homodimeric Ca²⁺-binding EF-hand protein (functional Ca²⁺ binding only via the C-terminal EF-hand) that undergoes Ca²⁺-dependent nuclear-to-cytoplasmic translocation; in the nucleus it associates with rDNA and RNA Polymerase I to promote rRNA synthesis and cancer metastasis, and in the cytoplasm it interacts with multiple partners including p53 (promoting its degradation to drive adipogenesis and liver fibrosis), GRP78 (activating IRE1α-XBP1 ER stress via competitive binding), myosin-9 (driving cytoskeletal reorganization and renal EMT), calmodulin (dysregulating CaMKK2/AMPK signaling), and HRD1 (ubiquitinating GSK3β/CK1α to activate Wnt/β-catenin in kidney injury), while its expression is transcriptionally regulated upstream by TFAP2B, NF-κB/p65, and estrogen signaling, and its protein level is post-translationally stabilized by S100A14 heterodimerization.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"S100A16 is a homodimeric EF-hand calcium-binding protein that functions as a calcium-sensitive signaling hub linking nucleolar ribosome biogenesis, ER stress, cytoskeletal remodeling, and multiple proliferative and fibrogenic signaling cascades. Ca²⁺ binding occurs exclusively through the C-terminal EF-hand and triggers translocation from nucleoli to the cytoplasm, where S100A16 engages distinct partners: it competes with IRE1α for GRP78 binding to activate ER stress via IRE1α/XBP1 splicing [PMID:34645789], interacts with myosin-9 to reorganize F-actin during epithelial–mesenchymal transition [PMID:32094322], binds calmodulin to modulate the CaM/CAMKK2/AMPK axis in hepatic lipogenesis and cardiac injury [PMID:31069793, PMID:39613175], promotes HRD1-mediated ubiquitination and degradation of GSK3β/CK1α to activate Wnt/β-catenin signaling [PMID:35279748], and binds p53 to induce its degradation thereby de-repressing adipogenesis and hepatic stellate cell activation [PMID:21266506, PMID:35914619]. In the nucleolus, S100A16 associates with rDNA and the RNA Pol I catalytic subunit RPA194 to drive rRNA biogenesis, and its loss suppresses metastasis in breast cancer models [PMID:40846689]. Transcription of S100A16 is directly activated by TFAP2B and NF-κB/p65, and its protein is post-translationally stabilized by S100A14, which cooperates with S100A16 to suppress p53 [PMID:38710691, PMID:39613175, PMID:41799516].\",\n  \"teleology\": [\n    {\n      \"year\": 2006,\n      \"claim\": \"Establishing the biochemical identity of S100A16 as a Ca²⁺-binding EF-hand protein answered the fundamental question of whether this orphan S100 family member actually senses calcium and where it resides in cells.\",\n      \"evidence\": \"Recombinant protein purification with flow dialysis, Trp fluorescence, and live-cell imaging in glioblastoma cells\",\n      \"pmids\": [\"17030513\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Target proteins recognized by the Ca²⁺-induced hydrophobic patch were not identified\", \"Mechanism of nucleolar retention and Ca²⁺-dependent export was not defined\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Atomic-resolution structures revealed that S100A16 undergoes unusually minimal conformational change upon Ca²⁺ binding, raising the question of how it achieves target discrimination despite a limited open-to-closed transition.\",\n      \"evidence\": \"X-ray crystallography and NMR solution structures in apo and Ca²⁺-bound states\",\n      \"pmids\": [\"21046186\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No structure of S100A16 bound to any target peptide or protein\", \"Functional consequence of the minimal conformational change for downstream signaling was not tested\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Identification of p53 as a direct binding partner established that S100A16 functions as a negative regulator of p53 signaling, providing the first mechanistic link to proliferation and adipogenesis.\",\n      \"evidence\": \"Co-immunoprecipitation of S100A16–p53 with functional readout (p53-responsive gene expression, adipogenesis) in 3T3-L1 cells\",\n      \"pmids\": [\"21266506\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism by which S100A16 binding leads to p53 inactivation/degradation was not resolved\", \"Structural basis of the S100A16–p53 interaction was unknown\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Discovery that S100A14 physically interacts with and post-translationally stabilizes S100A16 protein identified an intra-family regulatory mechanism and raised the question of how S100A16 levels are controlled independently of transcription.\",\n      \"evidence\": \"Yeast two-hybrid, reciprocal Co-IP, and cycloheximide chase in epithelial cell lines\",\n      \"pmids\": [\"24086685\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"The degradation pathway responsible for S100A16 turnover (neither proteasomal nor lysosomal) was not identified\", \"Stoichiometry and structural basis of the S100A14–S100A16 heterodimer were unknown\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Demonstration that S100A16 biases mesenchymal stem cell differentiation toward adipogenesis (via PPARγ) and away from osteogenesis (via RUNX2) established its role as a lineage switch, with JNK and ERK1/2 as downstream effectors.\",\n      \"evidence\": \"Overexpression and knockout in BM-MSCs with luciferase reporter assays and differentiation staining\",\n      \"pmids\": [\"23526364\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct versus indirect regulation of PPARγ and RUNX2 promoters was not determined\", \"Whether the p53 interaction contributes to the lineage switch was not tested\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Epistasis experiments showed that S100A16 drives EMT in breast cancer cells through Notch1-dependent upregulation of ZEB1/ZEB2, establishing the first cancer-relevant signaling axis downstream of S100A16.\",\n      \"evidence\": \"Retroviral overexpression with Notch1 siRNA rescue, migration/invasion assays in MCF-7 cells\",\n      \"pmids\": [\"25287362\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"How S100A16 activates Notch1 (ligand-dependent versus transcriptional) was not resolved\", \"In vivo metastasis validation was lacking\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Kinase inhibitor epistasis placed AKT and ERK1/2 as convergent effectors of S100A16-driven proliferation and invasion in prostate cancer, reinforcing the PI3K/AKT and MAPK axes as recurrent downstream pathways.\",\n      \"evidence\": \"Stable overexpression/shRNA with LY294002 and PD98059 inhibitors in DU-145 cells\",\n      \"pmids\": [\"27240591\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct upstream mechanism by which S100A16 activates PI3K and MAPK was unknown\", \"Receptor or adaptor protein mediating activation was not identified\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Finding that exosome-delivered signals induce S100A16 nuclear translocation and PHB-1-dependent mitochondrial protection in SCLC cells revealed a non-cell-autonomous mode of S100A16 regulation and a survival function at mitochondria.\",\n      \"evidence\": \"Exosome isolation, GW4869 inhibition, PHB-1 siRNA epistasis, JC-1 and apoptosis assays in SCLC cells\",\n      \"pmids\": [\"30183374\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"The exosomal cargo responsible for S100A16 induction was not identified\", \"Whether S100A16 directly binds PHB-1 was not tested\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Identification of calmodulin as a direct S100A16 partner and demonstration that S100A16 regulates the CaM/CAMKK2/AMPK axis in hepatic lipogenesis connected S100A16 to metabolic Ca²⁺ signaling in vivo.\",\n      \"evidence\": \"Co-IP of CaM–S100A16, transgenic and knockdown mice on high-fat diet\",\n      \"pmids\": [\"31069793\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Structural basis and Ca²⁺ dependence of S100A16–CaM interaction were not characterized\", \"Whether S100A16 activates or inhibits CaM was not clarified biochemically\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Mass spectrometry identification of myosin-9 as an S100A16 partner during TGF-β-induced EMT in kidney tubular cells linked S100A16 to actin cytoskeletal reorganization and renal fibrosis, validated in genetic mouse models.\",\n      \"evidence\": \"MS screening, Co-IP, F-actin imaging, S100A16 transgenic and heterozygous mice in UUO model\",\n      \"pmids\": [\"32094322\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Domain of myosin-9 involved and Ca²⁺ dependence of the interaction were not mapped\", \"Whether S100A16 modulates myosin-9 motor activity or only scaffolding was unresolved\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Demonstration that S100A16 activates STAT3/TWIST1 in pancreatic cancer and synergizes with gemcitabine upon knockdown added STAT3 to the portfolio of S100A16-activated pathways and provided therapeutic rationale.\",\n      \"evidence\": \"shRNA knockdown plus gemcitabine in vitro and xenograft models of PDAC\",\n      \"pmids\": [\"33359364\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct versus indirect STAT3 activation mechanism was not resolved\", \"Upstream receptor or kinase mediating STAT3 phosphorylation was not identified\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Competitive binding experiments showed that S100A16 displaces IRE1α from GRP78, releasing IRE1α for autophosphorylation and XBP1 splicing — providing the first defined molecular mechanism by which S100A16 triggers ER stress.\",\n      \"evidence\": \"Competitive Co-IP (GRP78–IRE1α vs GRP78–S100A16), BAPTA-AM Ca²⁺ chelation, Western blot for p-IRE1α and XBP1s in HK-2 cells\",\n      \"pmids\": [\"34645789\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether S100A16 directly binds IRE1α in addition to GRP78 was not tested\", \"Structural details of the GRP78–S100A16 interface were unknown\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Discovery that S100A16 facilitates HRD1 E3 ligase-mediated ubiquitination of GSK3β and CK1α to activate Wnt/β-catenin signaling established a direct link between S100A16 and destruction complex regulation during kidney injury.\",\n      \"evidence\": \"S100A16 knockout mice (IRI model), ubiquitination assays, ICG-001 Wnt inhibitor epistasis in NRK-49F fibroblasts\",\n      \"pmids\": [\"35279748\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether S100A16 directly binds HRD1 or acts as a scaffold was not distinguished\", \"Generalizability of the HRD1–GSK3β axis beyond renal fibroblasts was not tested\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"In vivo genetic evidence (KO and transgenic mice) demonstrated that S100A16 drives hepatic stellate cell activation and liver fibrosis by degrading p53 to upregulate CXCR4, which then activates ERK1/2 and AKT — connecting the p53 interaction to a disease-relevant in vivo phenotype.\",\n      \"evidence\": \"S100a16 KO and transgenic mice, CCl4 and bile duct ligation fibrosis models, RNA-seq, Co-IP of S100A16–p53\",\n      \"pmids\": [\"35914619\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of p53 degradation (ubiquitin ligase involvement, proteasomal pathway) was not defined\", \"Whether S100A16 affects p53 in non-fibrotic contexts in vivo was not tested\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"MANF was identified as a downstream effector through which S100A16 deletion protects against alcohol-induced fatty liver, revealing an S100A16–MANF–ER stress axis in hepatic lipid metabolism.\",\n      \"evidence\": \"S100a16 KO and transgenic mice in Gao-binge alcohol model, MANF siRNA epistasis in primary hepatocytes\",\n      \"pmids\": [\"37928262\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether S100A16 directly regulates MANF transcription or protein stability was not determined\", \"Relationship between the MANF axis and the previously identified CaM/CAMKK2 axis in the liver was not examined\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"ChIP and reporter assays identified TFAP2B and NF-κB/p65 as direct transcriptional activators of the S100A16 promoter, answering the long-standing question of how S100A16 expression is induced during injury.\",\n      \"evidence\": \"ChIP and luciferase reporter for TFAP2B on S100A16 promoter (renal cells), NF-κB/p65 binding to S100A16 promoter (cardiomyocytes), I/R models\",\n      \"pmids\": [\"38710691\", \"39613175\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Relative contributions of TFAP2B versus NF-κB in different tissues were not compared\", \"Epigenetic regulation of the S100A16 locus was not explored\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Identification of MOV10 RNA helicase as an S100A16 binding partner that stabilizes ITGA3 mRNA revealed a previously unrecognized role for S100A16 in post-transcriptional gene regulation in lung adenocarcinoma.\",\n      \"evidence\": \"Co-IP (S100A16–MOV10), RNA immunoprecipitation (MOV10–ITGA3 mRNA), actinomycin D chase in lung cancer cells\",\n      \"pmids\": [\"39450567\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether S100A16 modulates MOV10 helicase activity directly was not tested\", \"Generalizability of S100A16–MOV10 interaction to other cancer types or normal tissue was unknown\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"ChIP-MS at rDNA loci placed S100A16 in a complex with RPA194 (RNA Pol I catalytic subunit), demonstrating that nucleolar S100A16 directly participates in rRNA biogenesis and that this function is required for metastatic capacity in breast cancer.\",\n      \"evidence\": \"Nucleolar proteomics, ChIP-MS at rDNA, RNA Pol I activity assay, in vivo metastasis model\",\n      \"pmids\": [\"40846689\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether S100A16 is a stable Pol I subunit or a transient co-factor was not resolved\", \"Ca²⁺ dependence of the nucleolar rDNA association was not tested\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Demonstration that S100A16 knockdown suppresses β-catenin nuclear translocation through a STAT3–RPN2–GSK3β axis in cervical cancer provided an additional cancer context for S100A16-driven Wnt/β-catenin activation.\",\n      \"evidence\": \"RNA-seq, nuclear/cytosolic fractionation, RPN2 siRNA and S100A16 rescue in HeLa/SiHa cells\",\n      \"pmids\": [\"40907797\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether S100A16 directly phosphorylates or scaffolds STAT3 activation was unknown\", \"Overlap with the HRD1-mediated GSK3β degradation mechanism was not examined\"]\n    },\n    {\n      \"year\": 2026,\n      \"claim\": \"Reconstitution of the S100A14/S100A16 complex showed cooperative suppression of p53 stability and transcriptional activity, clarifying the functional significance of the S100A14-mediated stabilization of S100A16 first reported in 2013.\",\n      \"evidence\": \"Co-IP, CHX chase, dual-luciferase p53 reporter assay, siRNA epistasis in pancreatic cancer cells\",\n      \"pmids\": [\"41799516\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Ubiquitin ligase recruited by the S100A14/S100A16 complex to degrade p53 was not identified\", \"Structural basis of the heterodimeric complex was not determined\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The mechanism by which S100A16 selects among its diverse binding partners in different cellular compartments — and whether Ca²⁺-dependent conformational changes, post-translational modifications, or heterodimer formation govern this selectivity — remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No structure of S100A16 bound to any target protein exists\", \"Compartment-specific interactome has not been systematically mapped\", \"Relative affinities for GRP78, p53, CaM, myosin-9, and RPA194 have not been compared quantitatively\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [2, 8, 11, 13, 14]},\n      {\"term_id\": \"GO:0008092\", \"supporting_discovery_ids\": [9]},\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [11, 13]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005730\", \"supporting_discovery_ids\": [0, 22]},\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [0, 2, 7]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [0, 2, 11]},\n      {\"term_id\": \"GO:0005783\", \"supporting_discovery_ids\": [11]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [5, 6, 10, 12, 13, 21]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [13, 14, 23]},\n      {\"term_id\": \"R-HSA-8953854\", \"supporting_discovery_ids\": [22]},\n      {\"term_id\": \"R-HSA-8953897\", \"supporting_discovery_ids\": [11, 16]},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [4, 8, 16]}\n    ],\n    \"complexes\": [\n      \"S100A14/S100A16 heterodimer\"\n    ],\n    \"partners\": [\n      \"S100A14\",\n      \"TP53\",\n      \"GRP78\",\n      \"MYH9\",\n      \"CALM1\",\n      \"SYVN1\",\n      \"RPA194\",\n      \"MOV10\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"mechanistic_narrative\": \"S100A16 is an EF-hand Ca²⁺-binding protein that functions as a Ca²⁺-dependent signaling hub linking nucleolar ribosome biogenesis, epithelial–mesenchymal transition, adipogenesis, and organ fibrosis. Structurally, it forms a homodimer that binds Ca²⁺ exclusively through the C-terminal EF-hand, with minimal conformational change upon Ca²⁺ binding owing to strong inter-helical hydrophobic contacts [PMID:17030513, PMID:21046186]. In the nucleus, S100A16 associates with RNA Polymerase I at rDNA loci to promote rRNA synthesis and metastasis [PMID:40846689]; Ca²⁺ elevation drives its translocation to the cytoplasm, where it engages diverse partners—p53 (promoting its degradation to drive adipogenesis and hepatic stellate cell activation) [PMID:21266506, PMID:35914619], GRP78 (competitively releasing IRE1α to activate ER stress) [PMID:34645789], myosin-9 (reorganizing the actin cytoskeleton during renal EMT) [PMID:32094322], calmodulin (dysregulating the CaMKK2/AMPK axis) [PMID:31069793, PMID:39613175], and the E3 ligase HRD1 (ubiquitinating GSK3β/CK1α to activate Wnt/β-catenin signaling in kidney injury) [PMID:35279748]. S100A16 protein levels are post-translationally stabilized by heterodimerization with S100A14, and its transcription is directly activated by TFAP2B and NF-κB/p65 and repressed by estrogen signaling [PMID:24086685, PMID:38710691, PMID:33921267, PMID:24501224].\",\n  \"teleology\": [\n    {\n      \"year\": 2006,\n      \"claim\": \"Established that S100A16 is a homodimeric Ca²⁺-binding protein using only the C-terminal EF-hand, answering the fundamental question of how this atypical S100 member senses calcium and revealing its Ca²⁺-dependent nucleolar-to-cytoplasmic translocation.\",\n      \"evidence\": \"Recombinant protein flow dialysis, Trp fluorescence spectroscopy, immunofluorescence in glioblastoma cells\",\n      \"pmids\": [\"17030513\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Target-binding surface only inferred from hydrophobic patch exposure; no target protein identified\", \"Mouse S100A16 did not expose a hydrophobic patch—species-specific functional differences unresolved\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Atomic-resolution structures of apo and Ca²⁺-bound S100A16 explained why Ca²⁺-induced conformational change is unusually modest, resolving the paradox of weak target-protein interaction detected biochemically.\",\n      \"evidence\": \"Dual NMR solution structure and X-ray crystallography of human S100A16\",\n      \"pmids\": [\"21046186\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No structure of S100A16 bound to a target peptide or protein\", \"Functional consequence of minimal conformational change for downstream signaling not tested\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Identified the first cellular function—promotion of adipogenesis—and the first direct binding partner, p53, establishing that S100A16 suppresses p53-dependent transcription and that Ca²⁺-induced cytoplasmic translocation regulates this adipogenic activity.\",\n      \"evidence\": \"Overexpression/RNAi in 3T3-L1 preadipocytes; co-immunoprecipitation of S100A16–p53; Ca²⁺ ionophore translocation\",\n      \"pmids\": [\"21266506\", \"21871643\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of p53 degradation not defined (direct or via E3 ligase)\", \"Whether Ca²⁺-dependent translocation is required for all S100A16 functions unclear\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Revealed that S100A14 heterodimerizes with S100A16 and stabilizes it post-translationally, and that S100A16 reciprocally regulates mesenchymal stem cell fate by promoting adipogenesis via JNK and inhibiting osteogenesis via ERK1/2.\",\n      \"evidence\": \"Yeast two-hybrid, co-IP, cycloheximide chase (S100A14–S100A16); luciferase reporters for PPARγ/RUNX2 in BM-MSCs\",\n      \"pmids\": [\"24086685\", \"23526364\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Degradation pathway for S100A16 protein itself not identified (proteasome- and lysosome-independent)\", \"S100A14–S100A16 stoichiometry and structural basis unresolved\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Extended S100A16 function to cancer EMT: in breast cancer cells it drives Notch1-dependent E-cadherin loss, and estrogen signaling was shown to directly repress the S100A16 promoter, linking hormonal regulation to its adipogenic and EMT roles.\",\n      \"evidence\": \"Retroviral overexpression/Notch1 siRNA rescue in MCF-7; luciferase reporter for E2-mediated S100A16 promoter repression; ovariectomized rat model\",\n      \"pmids\": [\"25287362\", \"24501224\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Notch1 activation mechanism by S100A16 not defined (direct interaction vs. transcriptional)\", \"Estrogen receptor subtype mediating S100A16 repression not identified\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Demonstrated that exosome-transferred S100A16 protects cancer cells from apoptosis via mitochondrial membrane potential maintenance dependent on prohibitin-1, and that S100A16 suppresses proteasomal degradation of p53 to maintain cancer stemness factors Oct4/Nanog.\",\n      \"evidence\": \"HBMEC exosome transfer to SCLC cells with PHB-1 epistasis; cervical carcinoma spheroid assay with proteasome inhibitor rescue\",\n      \"pmids\": [\"30183374\", \"29928366\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct S100A16–PHB1 physical interaction not tested\", \"Contradictory roles of S100A16 on p53 (degradation in adipogenesis vs. stabilization in stemness) not reconciled\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Identified calmodulin as a direct S100A16 interactor mediating hepatic lipogenesis via the CaMKK2/AMPK axis, and placed S100A16 downstream of Snail in a chemoresistance circuit operating through AKT/Bcl-2.\",\n      \"evidence\": \"Co-IP (S100A16–CaM) in transgenic/knockout mice on HFD; siRNA knockdown in drug-resistant bladder cancer cells\",\n      \"pmids\": [\"31069793\", \"31118765\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether S100A16 competes with Ca²⁺/CaM targets or modulates CaM conformation not distinguished\", \"Snail–S100A16 transcriptional regulation not confirmed by promoter binding assay\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Identified myosin-9 as a Ca²⁺-dependent S100A16 partner driving actin cytoskeletal reorganization and renal EMT, validated in transgenic and knockout mice undergoing ureteral obstruction.\",\n      \"evidence\": \"Mass spectrometry pulldown for S100A16 partners; UUO model in S100A16 transgenic/heterozygous-KO mice; F-actin immunofluorescence\",\n      \"pmids\": [\"32094322\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Binding interface on myosin-9 and whether S100A16 modulates myosin ATPase activity unknown\", \"Relative contribution of myosin-9 vs. GRP78 pathways in renal fibrosis not delineated\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Defined a competitive binding mechanism at the ER: S100A16 sequesters GRP78 away from IRE1α, triggering IRE1α autophosphorylation and XBP1 splicing, establishing S100A16 as a Ca²⁺-dependent activator of the unfolded protein response in renal fibrosis.\",\n      \"evidence\": \"Co-IP showing competitive S100A16–GRP78 vs. IRE1α–GRP78 binding; BAPTA-AM reversal; UUO mouse model\",\n      \"pmids\": [\"34645789\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether S100A16–GRP78 interaction occurs at other ER stress branches (PERK, ATF6) not tested\", \"Structural basis for GRP78 competition not resolved\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Placed S100A16 downstream of NF-κB/p65 transcriptional control in gastric cancer, and identified ZO-2 as an interaction partner whose ubiquitin-dependent degradation drives S100A16-mediated EMT and invasion.\",\n      \"evidence\": \"Dual-luciferase reporter for NF-κB at S100A16 promoter; ADAMTS19–P65 co-IP; proteomic identification and co-IP of S100A16–ZO-2; ubiquitination assay\",\n      \"pmids\": [\"33921267\", \"34650982\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"E3 ligase responsible for ZO-2 ubiquitination downstream of S100A16 not identified\", \"Whether NF-κB regulation of S100A16 is tissue-general or gastric cancer–specific unknown\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Established that S100A16 binds p53 to promote its degradation in hepatic stellate cells, driving CXCR4/ERK/AKT-dependent liver fibrosis, and that HRD1-mediated ubiquitination of GSK3β/CK1α downstream of S100A16 activates Wnt/β-catenin signaling in acute kidney injury—both validated by genetic knockout in vivo.\",\n      \"evidence\": \"S100A16-KO and transgenic mice in liver fibrosis and renal IRI models; co-IP (S100A16–p53); ubiquitination assays (HRD1–GSK3β/CK1α); Wnt inhibitor epistasis\",\n      \"pmids\": [\"35914619\", \"35279748\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether S100A16 directly activates HRD1 E3 ligase activity or recruits substrates not distinguished\", \"How p53 degradation is mechanistically accomplished (proteasomal pathway involvement) remains incomplete\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Identified TFAP2B as a direct transcriptional activator of S100A16 via ChIP, and confirmed that S100A16–calmodulin interaction mediates cardiomyocyte injury after ischemia/reperfusion through the CaMKK2/AMPK pathway downstream of NF-κB/p65 promoter activation.\",\n      \"evidence\": \"ChIP and luciferase assay (TFAP2B at S100A16 promoter; HIF-1α at HRD1 promoter); S100A16-KO rat cells; myocardial IRI model with adenoviral knockdown\",\n      \"pmids\": [\"38710691\", \"39613175\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether TFAP2B and NF-κB/p65 cooperate at the S100A16 promoter or act in distinct tissues not tested\", \"Upstream signals activating TFAP2B in hypoxia not defined\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Revealed that S100A16 localizes to the nucleolus and associates with RNA Polymerase I at rDNA loci, directly promoting rRNA synthesis; its loss reverses EMT and reduces metastasis, connecting ribosome biogenesis to the metastatic program.\",\n      \"evidence\": \"ChIP-MS (S100A16 at rDNA with RPA194); rRNA synthesis assay; CRISPR knockout; in vivo metastasis model in breast cancer\",\n      \"pmids\": [\"40846689\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism by which S100A16 activates Pol I (cofactor recruitment vs. chromatin remodeling) not defined\", \"Whether nucleolar function is Ca²⁺-dependent or constitutive not tested\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the structural basis for S100A16 target discrimination among its many partners, how its apparently opposing effects on p53 (degradation in adipogenesis/fibrosis vs. stabilization in stemness) are contextually regulated, and the relative contribution of nucleolar rRNA synthesis versus cytoplasmic EMT pathways to its pro-metastatic activity.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No co-crystal structure of S100A16 with any target protein\", \"Context-dependent p53 regulation mechanism unresolved\", \"Relative importance of nuclear vs. cytoplasmic functions in different disease settings not systematically compared\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [2, 11, 12, 16, 20, 21, 29]},\n      {\"term_id\": \"GO:0008092\", \"supporting_discovery_ids\": [14]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005730\", \"supporting_discovery_ids\": [0, 28]},\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [0, 2, 10]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [0, 2, 14, 16]},\n      {\"term_id\": \"GO:0005783\", \"supporting_discovery_ids\": [16]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [2, 5, 6, 9, 13, 15, 17, 20, 25, 27]},\n      {\"term_id\": \"R-HSA-8953854\", \"supporting_discovery_ids\": [28]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [4, 18, 20, 29]},\n      {\"term_id\": \"R-HSA-8953897\", \"supporting_discovery_ids\": [16, 25]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [10, 13, 25]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [2, 5, 22]}\n    ],\n    \"complexes\": [\n      \"S100A14/S100A16 heterodimer\",\n      \"S100A16 homodimer\"\n    ],\n    \"partners\": [\n      \"S100A14\",\n      \"TP53\",\n      \"HSPA5\",\n      \"MYH9\",\n      \"CALM1\",\n      \"SYVN1\",\n      \"MOV10\",\n      \"POLR1A\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}